Citation for published version:

Kumpan, K, Nathubhai, A, Zhang, C, Wood, PJ, Lloyd, MD, Thompson, AS, Haikarainen, T, Lehtio, L & Threadgill, MD 2015, 'Structure-based design, synthesis and evaluation *in vitro* of aryl naphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrase', *Bioorganic and Medicinal Chemistry*, vol. 23, pp. 3013-3032. <https://doi.org/10.1016/j.bmc.2015.05.005>

DOI:

[10.1016/j.bmc.2015.05.005](https://doi.org/10.1016/j.bmc.2015.05.005)

Publication date:

2015

Document Version

Early version, also known as pre-print

[Link to publication](#)

University of Bath

Alternative formats

If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Graphical Abstract

To create your abstract, type over the instructions in the template box below.
Fonts or abstract dimensions should not be changed or altered.

Structure-based design, synthesis and evaluation *in vitro* of aryl-naphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases

Katerina Kumpan, Amit Nathubhai,
Chenlu Zhang, Pauline J. Wood,
Matthew D. Lloyd, Andrew S.
Thompson, Teemu Haikarainen, Lari
Lehtiö, Michael D. Threadgill
*Dept. Pharmacy & Pharmacology,
University of Bath, Bath BA2 7AY, UK*

Leave this area blank for abstract info.

R^4 = H, OMe, CF_3 , Cl, Br
 IC_{50} = 1 – 97 nM (tankyrase-2)
 IC_{50} = 1 – 5 μ M (PARP-1)

W or X or Y or Z = N
Inactive vs. tankyrase-2

Structure-based design, synthesis and evaluation *in vitro* of aryl naphthyridinones, arylpyridopyrimidinones and their tetrahydro derivatives as inhibitors of the tankyrases

Katerina Kumpan,^a Amit Nathubhai,^a Chenlu Zhang,^{a,b} Pauline J. Wood,^a Matthew D. Lloyd,^a Andrew S. Thompson,^a Teemu Haikarainen,^c Lari Lehtiö^c and Michael D. Threadgill^{a,*}

^a Medicinal Chemistry, Department of Pharmacy & Pharmacology, University of Bath, Claverton Down, Bath BA2 7AY, UK

^b Department of Pharmacy, Shandong University, Jinan 250100, China

^c Biocenter Oulu and Faculty of Biochemistry and Molecular Medicine, University of Oulu, Oulu, Finland

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

Tankyrase

TNKS

Naphthyridinone

7-Aryl-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-one

Crystal structure

ABSTRACT

The tankyrases are members of the PARP superfamily; they poly(ADP-ribosyl)ate their target proteins using NAD⁺ as a source of electrophilic ADP-ribosyl units. The three principal protein substrates of the tankyrases (TRF1, NuMA and axin) are involved in replication of cancer cells; thus inhibitors of the tankyrases may have anticancer activity. Using structure-based drug design and by analogy with known 3-arylisquinolin-1-one and 2-arylquinazolin-4-one inhibitors, series of aryl naphthyridinones, arylpyridopyrimidinones and their tetrahydro-derivatives were synthesised and evaluated *in vitro*. 7-Aryl-1,6-naphthyridin-5-ones, 3-aryl-2,6-naphthyridin-1-ones and 3-aryl-2,7-naphthyridin-1-ones were prepared by acid-catalysed cyclisation of the corresponding arylethynylpyridinenitriles or reaction of bromopyridinecarboxylic acids with β -diketones, followed by treatment with NH₃. The 7-aryl-1,6-naphthyridin-5-ones were methylated at 1-N and reduced to 7-aryl-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones. Cu-catalysed reaction of benzamidines with bromopyridinecarboxylic acids furnished 2-arylpyrido[2,3-*d*]pyrimidin-4-ones. Condensation of benzamidines with methyl 1-benzyl-4-oxopiperidine-3-carboxylate and deprotection gave 2-aryl-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-ones, aza analogues of the known inhibitor XAV939. Introduction of the ring-N in the aryl naphthyridinones and the arylpyridopyrimidinones caused >1000-fold loss in activity, compared with their carbocyclic isoquinolinone and quinazolinone analogues. However, the 7-aryl-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones showed excellent inhibition of the tankyrases, with some examples having IC₅₀ = 2 nM. One compound (7-(4-bromophenyl)-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-one) showed 70-fold selectivity for inhibition of tankyrase-2 vs. tankyrase-1. The mode of binding was explored through crystal structures of inhibitors in complex with tankyrase-2. © 2014 Elsevier Ltd. All rights reserved.

1. Introduction

The tankyrases (PARP-5a / TNKS-1 / ARTD5 and PARP-5b / TNKS-2 / ARTD6) are members of the poly(ADP-ribose)polymerase (PARP) superfamily of enzymes.¹ Considerable recent interest has been expressed in these enzymes,^{2–10} in view of their roles at the chromosomal telomeres, at the mitotic spindle and in signalling pathways. In common with other PARPs, the tankyrases transfer ADP-ribose units from substrate NAD⁺ to build poly(ADP-ribose)polymers on target proteins. TNKS-1 poly(ADP-ribosyl)ates TRF1 at the telomere, causing it to detach from the telomere and become ubiquitinated and targeted for destruction.^{11,12} This exposes the telomeric DNA, allowing access by the telomerase complex. Thus TNKS-1 activity is a positive

regulator of telomere length. Tankyrase activity is also critical for the correct functioning of the mitotic spindle, where its protein target is NuMA.¹³ TNKS-1 is also a component of the *wnt* signalling system,^{9,14} where it modifies axin. This leads to ubiquitinylation and destruction of the poly(ADPr)-axin, increasing levels of β -catenin and suppressing phosphorylated β -catenin. The net effect of this activity is a proliferative signal in the nucleus. The isoform TNKS-2 can substitute for TNKS-1 in many of these intracellular activities.^{11,15,16}

Tankyrases are over-expressed in several clinical cancers and cancer cell lines, including mammary¹⁷ and colorectal carcinomas,¹⁸ chronic myeloid leukaemia,¹⁹ and tumours in brain,²⁰ stomach²¹ and bladder.²² This over-expression indicates critical

* Corresponding author: Tel.: +44 1225 386840; FAX: +44 1225 386114; e-mail: m.d.threadgill@bath.ac.uk

Figure 1. Structures of reported inhibitors of the tankyrases.

roles for the tankyrases in tumours; they were proposed as therapeutic targets as long ago as 2006.²³ Their recent discovery⁹ as components of the proliferative *wnt* signalling pathway confirms this potential. Indeed, one tankyrase inhibitor has shown activity in an APC-mutant mouse model of colon cancer²⁴ and has been shown to cause apoptosis in neuroblastoma cells.⁸ The time is, therefore, ripe to explore the structure-based design and development of potent and selective inhibitors of the tankyrases.

The reported inhibitors of the tankyrases fall into two classes: those that bind in the nicotinamide-binding site as mimics of nicotinamide and those which are bound at other sites, including the adenine-binding site. Some recent inhibitors have been designed to occupy both sites simultaneously.

Examination of the crystal structure of the prototype inhibitor XAV939 **1** (Figure 1) bound into TNKS-2 reveals that the lactam makes H-bonds with the carbonyl and N–H of Gly¹⁰³² and the side-chain alcohol of Ser¹⁰⁶⁸.²⁵ There is also some evidence for π -stacking with Tyr¹⁰⁷¹. The side-chain 4-trifluoromethylphenyl projects into an adjacent hydrophobic cavity, forming a π -stack with Tyr¹⁰⁵⁰ and hydrophobic interactions with Pro¹⁰³⁴, Phe¹⁰³⁵ and Ile¹⁰⁷⁵.⁴ We have reported that 2-aryl-8-methylquinazolin-4-ones **2** and related 3,4-dihydroquinazolinones also inhibit the tankyrases strongly, with IC₅₀ values slightly higher than those of **1**.^{4,26} Molecular modelling studies indicated that the mode of binding of **2** is similar to that of **1**, with the aryl group projecting into the hydrophobic cavity.⁴ Very recently, we disclosed a large series of 5-substituted 3-arylisoquinolin-1-ones **3**, some of which (e.g. **3**; R^{4'} = R⁵ = Me) were more potent than **1**. Water-soluble tertiary amine analogues (e.g. **3**; R^{4'} = CH₂NMe₂, R⁵ = Me) retained potency.³ A crystal structure of **3** (R^{4'} = Cl, R⁵ = OMe) in complex with TNKS-2 (PDB code 4UVY) confirmed the mode of binding, with the lactam carbonyl oxygen accepting H-bonds from Gly¹⁰³² and Ser¹⁰⁶⁸ and the lactam N–H donating an H-bond to the carbonyl of Gly¹⁰³².³ The chlorophenyl unit occupies the hydrophobic cavity, with the chlorine located at the entrance to a narrow tunnel leading to the exterior. Extensions at R^{4'} project deep into this tunnel. Although the lactam carbonyl and the phenyl in the hydrophobic pocket are essential for binding, the N–H of the lactam is less important, in that flavones such as **4** are active.^{27,28} The [1,2,4]triazolo[4,3-*b*]pyridazine **5** has also been shown crystallographically to bind in the nicotinamide-binding pocket, with 1-N making a H-bond to N–H of Gly¹⁰³², 2-N making a H-bond with OH of Ser¹⁰⁶⁸ and the exocyclic N–H bonding with the C=O of Gly¹⁰³²; the phenol occupies the hydrophobic cavity.² Curiously, this compound is selective for inhibition of TNKS-1 (IC₅₀ = 12 nM) vs. TNKS-2 (IC₅₀ = 200 nM). IWR1 **6** binds solely at the nearby adenosine-binding site,²⁹ whereas **7**⁷ and **8**¹⁰ occupy both the nicotinamide-binding site and the adenosine-binding site.

2. Results & Discussion

2.1. Design of inhibitors

In the light of the potency and selectivity of our series of 3-arylisoquinolin-1-ones **3**³ and 2-arylquinazolin-4-ones **2**⁴ for inhibition of the tankyrases, we sought to extend the structure-activity relationships (SARs) into aza analogues. Figure 2 shows the structures of these candidate inhibitors. Introducing a nitrogen into the carbocyclic ring of **3** (in naphthyridinones **9–11**) will have two potential effects, electron-deficiency in the bicycle and weak basicity or H-bonding involving the N-lone pair. *Para*-substitution was found to be optimum in the phenyl rings of **2**⁴ and **3**³; thus only *para*-substituted phenyl rings were targeted in the present work. The lactam of **9–11** was expected to form the usual H-bonds with Ser¹⁰⁶⁸ and Gly¹⁰³² (TNKS-2 numbering), mimicking the nicotinamide of NAD⁺. The phenyl ring should occupy the adjacent hydrophobic cavity, making hydrophobic and π -stacking interactions therein, with the *para*-substituent projecting into the distal tunnel (Figure 3 shows a cartoon of the binding pocket). In the 2-arylquinazolin-4-one series **2**, a small substituent, e.g. Me, at the 8-position slightly improved potency.³ Similarly, 5-methyl-3-arylisoquinolin-1-ones (**3**; R⁵ = Me) generally had higher activity than their 5-fluoro (**3**; R⁵ = F), 5-hydroxy (**3**; R⁵ = OH) or 5-amino- (**3**; R⁵ = NH₂) counterparts.⁴ Thus we designed the 1-methyl-naphthyridin-5-ones **12** with the N-methyl occupying the same pocket in the enzyme. Of course, this makes major changes in electron-distribution in the bicyclic core and **12** are cationic. Similarly, the N-oxide in **13** would occupy the same pocket but without overall charge. The arylpyridopyrimidinones **14–16** are aza analogues of the active quinazolinones **3**. As for **9–11**, the additional nitrogen may make H-bonds.

Unlike PARP-1, the nicotinamide-binding site of the tankyrases can accommodate a (partly) saturated ring mimicking the pyridinium of NAD⁺, as shown by the activity of **1**. Thus we chose to explore the tetrahydro analogues **17** and **18**. In the 7-aryl-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones **17**, the left ring has three contiguous sp²-hybridised atoms (presumably coplanar with the pyridinone) and three sp³ methylenes. Thus the conformation may be slightly different to that of **1** but the N-Me should occupy the same space as the 5-Me in **3** (R⁵ = Me) and the 8-Me in **2**. The tetrahydropyridopyrimidinones **18** (especially **18d**, R = CF₃) are strict analogues of **1**, where the neutral lipophilic sulfur is replaced by a secondary amine. This amine should be protonated at physiological pH, so **18** should have the same conformation as **1** but will test the tolerance of the binding pocket to positive charge.

Figure 2. Structures of aryl naphthyridinones **9–13**, arylpyridopyrimidinones **14–16**, aryltetrahydronaphthyridinones **17** and aryltetrahydropyridopyrimidinones **18**, designed as inhibitors of the tankyrases. R = H, Me, OMe, CF₃, Cl, Br, NH₂, OH, -C≡CPh, etc.

2.2. Chemical synthesis

The initial targets for synthesis were the 7-aryl-1,6-naphthyridin-5-ones **9**, the 3-aryl-2,7-naphthyridin-1-ones **10** and the 3-aryl-2,6-naphthyridin-1-ones **11**. Wibberley prepared **9a** in 1.6% yield from ethyl 2-methylpyridine-3-carboxylate and benzaldehyde, *via* **26a**.³⁰ Reaction of 2-(2-phenyl-2-oxoethyl)pyridine-3-carboxylic acid with ammonia gives **9a** directly in 80% yield.³¹ Nishiwaki *et al.* examined cyclisation of 2-phenylethynyl-3-cyanopyridine **25a** under various conditions.³² Under basic conditions, the principal product arose from hydration / 5-*exo*-dig cyclisation, whereas strong acid furnished an equimolar mixture of **26a** and **9a** from 6-*endo*-dig cyclisation of the intermediate amide. By contrast, Pt-catalysed cyclisation of **25a** is reported to afford a mixture of **9a** and 5-ethoxy-7-phenyl-1,6-naphthyridine in moderate yields.³³ This method also provides **10a** in low yield. Isomer **11a** has been prepared in low yield by debenzoylation of 1-benzyl-4-phenacylpyridine-3-carboxamide.³⁵ This route was developed by N-benylation off nicotinamide. Riessert attack of acetophenone enolate at the 4-position, acid-catalysed cyclisation and debenzoylation yields **11a**.³⁵ 3-Phenyl-2,6-naphthyridin-1-one **10a** was formed in poor yield by a curious route involving treatment of dimethyl 2-(4-methoxycarbonylpyridin-3-yl)malonate with NaCl in DMSO at high temperature, followed by reaction with ammonia.³⁶

Of these routes, we selected the acid-catalysed cyclisation of arylethynyl-cyanopyridines **25**, **28**, **35** (Scheme 1), as the diversity in the aryl group would be introduced through diversity in the starting arylethynes, many of which are commercially available or readily accessible synthetically. Arylethynes **21c–e,g,h**, which are not economically commercially available, were obtained by Sonogashira coupling of the corresponding iodoarenes **19c–e,g,h** with trimethylsilylethyne to give **20c–e,g,h**, followed by desilylation. The phenolic OH of 4-iodophenol had earlier been masked with benzyl, using benzyl bromide and caesium carbonate in DMF, giving **19h**. Similar coupling of 4-bromopyridine **22** with trimethylsilylethyne and subsequent desilylation afforded 4-eth-

Figure 3. Cartoon showing the relative positions of binding motifs in the structures of the tankyrases, with the inhibitor **3** (R⁴ = Cl, R⁵ = OMe) bound.

nylpyridine **21i** in moderate yield, *via* intermediate **20i**. Sonogashira coupling of the alkynes **21a–e,g,h,i** with appropriate halopyridinenitriles was then investigated. Coupling of the alkynes with 2-chloro-3-cyanopyridine **23** led to the key intermediates **25** in low yields, despite activation of the chloroarene by the adjacent ring-N and the electron-withdrawing nitrile. This parallels our experience with Suzuki couplings to 3-chloroisoquinolines.³ The poor yield was addressed in two ways. Firstly, 1,4-diarylbutadiynes were observed as major by-products, arising from oxidative Glaser homocoupling of the arylethynes.^{37,38} This was addressed by using an excess of the alkyne (wasteful) or by adding sodium ascorbate to the reaction mixture as an antioxidant. Addition of sodium ascorbate also led to higher yields in some of the couplings of **19** and **22** with trimethylsilylethyne. Also effective in raising the yields of **25** was replacement of the 2-chloropyridine **23** with the corresponding bromopyridine **24**. This educt was prepared by acetolysis of **23** with acetic acid and hydrolysis of the intermediate 2-acetoxy-3-cyanopyridine in boiling aqueous THF under neutral conditions to give 3-cyanopyridin-2-one. Conventional reagents (*e.g.* POBr₃, PBr₅) failed to give **24** but reaction with Bu₄NBr and P₂O₅ in toluene gave the bromopyridine in excellent overall yield. This 2-bromopyridine coupled with the range of arylethynes in moderate-to-good yields to give **25a–e,g,h,i**, catalysed by (Ph₃P)₂PdCl₂. Aqueous acid-catalysed cyclisation proceeded exclusively in the 6-*endo*-dig mode, affording mixtures of the 7-arylpyrano[4,3-*b*]pyridin-5-ones **26** and the 7-aryl-1,6-naphthyridin-5-ones **9**, from initial hydration to the carboxamide and trapping of the electrophile derived from the alkyne with either the oxygen or the nitrogen, respectively, of the amide. In many cases, these mixtures were separable with difficulty and **26** could be converted into **9** by treatment with ammonia in 2-methoxyethanol under pressure. However, it was more convenient to treat the mixtures directly with ammonia to afford good yields of **9**. The benzyl protection of **25h** was lost during the treatment with acid, forming **9i** directly.

Methylation of **9a–e,g** at 1-N was achieved with iodomethane in DMF, affording **12a–e,g**. The location of the methyl at 1-N was confirmed by HMBC correlations from NCH₃ to 2-C and from 2-H to NCH₃ and, in some cases, by nOe experiments. Interestingly, **9g**, carrying a primary aniline, was only methylated at 1-N to give **12g**. These quaternised naphthyridinium salts **12** were targets in their own right but were also precursors of the tetrahydro analogues **17**. Borane.pyridine complex has been reported³⁹ to reduce naphthyridinium species but, in the case of **12**, it was necessary to use formic acid as solvent for the reaction. The problem of decomposition of the borane complex by the acidic medium was overcome by adding the reductant in frequent small portions and **17a,c–f** were obtained in low yields.

The nucleophilicity of 1-N was also exploited in forming the N-oxides **13a,b** from **9a,b**, using anhydrous peroxytrifluoroacetic

Scheme 1. Synthetic approaches to target arynaphthyridinones **9-11** by acid-catalysed cyclisation of arylethynylpyridinenitriles, N-oxidation to **13**, methylation to **12**, **29a**, **36c** and reduction to the 7-aryl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones **17**. *Reagents & conditions:* i, BnBr, Cs₂CO₃, DMF; ii, Me₃SiC≡CH, (Ph₃P)₂PdCl₂, CuI, Na ascorbate, Et₃N, THF, Ar, 40°C; iii, Bu₄NF, THF; iv, AcOH, reflux; v, THF, H₂O, reflux; vi, Bu₄NBr, P₂O₅, PhMe, reflux; vii, **21**, (Ph₃P)₂PdCl₂, CuI, Na ascorbate, THF, Pr₂NH, Ar, 40°C; viii, aq. H₂SO₄ (9 M), reflux; ix, NH₃, MeO(CH₂)₂OH, pressure, 100°C; x, MeI, DMF; xi, Urea.H₂O₂, (F₃CCO)₂O, DMF, 0°C; xii, BH₃.pyridine, HCO₂H; xiii, LiNPr₂, solid CO₂, THF, Ar, -78°C; xiv, EtO₂CCl, Et₃N, THF, 0°C, then NH₃; xv, POCl₃, reflux.

acid generated *in situ* from urea/hydrogen peroxide complex and trifluoroacetic anhydride. We had previously used this system for the difficult N-oxidation of 8-cyanoquinoline to the N-oxide.⁴⁰ Although it was predictable that the oxidation had taken place at 1-N, in the light of methylation occurring exclusively at this site, it was important to provide evidence for the regiochemical identity of target compounds **13a,b**. In this case, the oxygen was located by examination of the ¹⁵N NMR chemical shifts. After assignment using ¹H-¹⁵N HMBC spectroscopy, the ¹⁵N chemical shifts for **9a** were shown to be 1-N (δ 278.87, HMBC correlation to 2-H and 8-H) and 6-N (δ 124.89, HMBC correlation to 8-H only), whereas those for **13a** were 1-N (δ 252.76; HMBC correlation to 2-H and 8-H) and 6-N (δ 129.56; correlation to 8-H only). The marked change in chemical shift of 1-N upon oxidation, compared with the small change for 6-N, confirms that oxidation took place at 1-N.

Oxidation of 3-phenyl-3,4-dihydro-2,7-naphthyridin-1-one (from acid-catalysed cyclisation of 3-cyano-4-(2-phenylethenyl)-pyridine) is reported to afford **11a**.⁴¹ In the present work, the 3-aryl-2,7-naphthyridin-1-ones **11** were approached through similar acid-catalysed cyclisations of arylethynylpyridinenitriles. Sonogashira couplings of 4-bromo-3-cyanopyridine **27** with the

range of arylethynes **21a,c-e,g** gave the required intermediates **28a,c-e,g** (Scheme 1) in moderate-to-good yields, in the presence of sodium ascorbate. Attempted couplings of **21b** and **21l** with **27** failed, despite the activation of the 4-bromopyridine component by the ring-N. Cyclisation by reaction of **28a,c** with hot aqueous sulfuric acid and treatment of the mixtures of 2,7-naphthyridin-1-ones and pyrano[3,4-*c*]pyridin-1-ones with ammonia under pressure gave the required 3-aryl-2,7-naphthyridin-1-ones **11a,c**. Curiously, although the major components of the product mixtures from the cyclisations of **28a,c** with sulfuric acid were the pyrano[3,4-*c*]pyridin-1-ones, the corresponding acid-catalysed reaction of the 4'-aminophenyl compound **28g** gave only the naphthyridinone **11g**, obviating the need for treatment with ammonia. One example, **11a**, was methylated at 7-N to provide the cation **29a** but all attempts to reduce this to 3-phenyl-5,6,7,8-tetrahydro-2,7-naphthyridin-1-one, by analogy with the preparation of **17**, failed.

Synthesis of synthesise 3-bromo-4-cyanopyridine **30** was required in approaching the 3-aryl-2,6-naphthyridin-1-ones **10a-e** in the same way. Lithiation of 3-bromopyridine **30** with LDA and quench of the anion with carbon dioxide gave the 4-carboxylic acid **31** in low yield. Conversion into the amide **32** and dehydration with POCl₃ gave the required nitrile **34**. Sonogashira coup-

lings attached the arylalkynes **21a-e**, affording **35a-e**. Cyclisation and treatment with ammonia furnished the targets **10a-c,e** but the trifluoromethylphenylalkyne in **35d** was insufficiently nucleophilic to react. Only one example, **10c**, could be methylated at 6-N (affording **36c**) and this cation could not be reduced.

Scheme 2 shows development of an alternative strategy to access the target arylnaphthyridinones. We previously reported a one-pot tandem Hurtley–retro-Claisen–cyclisation sequence to assemble isocoumarins from 2-bromo-3-nitrobenzoic acid and symmetrical and unsymmetrical β -diketones.⁴² This was adapted to provide those arylnaphthyridinones which had been inaccessible or accessible only with difficulty by the route shown in Scheme 1. In view of the difficulties experienced in separating mixtures of isocoumarins generated from unsymmetrical β -diketones,⁴² only symmetrical 1,3-diarylpropane-1,3-diones **37** were used in the present study. In contrast to the successful Hurtley couplings with 2-bromo-3-nitrobenzoic acid and with 3-bromothiophene-4-carboxylic acid,^{42,43} only one example, **31**, gave a usable yield of the corresponding pyranopyridinone **41a**, with **37a** and CuI in boiling DMF. Liu *et al.* recently published⁴⁴ a transition-metal-free variant of the Hurtley reaction, in which 2-bromobenzoic acids are heated with β -diketones in the presence of Cs₂CO₃ in acetonitrile; the S_NAr reaction is followed by retro-Claisen cleavage and cyclisation to form isocoumarins. Adapting this procedure to our target naphthyridinones, 2-bromopyridine-3-carboxylic acid **38** was treated with excesses of the symmetrical β -diketones **37b,c,e,f** and Cs₂CO₃ in boiling acetonitrile to give excellent yields of the corresponding 7-arylpyrano[4,3-*b*]pyridin-5-ones **26b,c,e,f**. The reaction failed for the electron-deficient β -diketones **37d,k**, even when the reaction temperature was increased by the use of boiling propionitrile as solvent. The C–Br bond is activated by the adjacent nitrogen in **38**; it is also activated but to a lesser extent in 4-bromopyridine-3-carboxylic acid **39**. Correspondingly, **39** reacted with the β -diketones **37b,c,f** to give the 3-arylpyrano[3,4-*c*]pyridin-1-ones **40b,c,f**. Yields were lower, especially for **40f**, corresponding to the need for a strongly nucleophilic electron-rich enolate. 3-Bromopyridine-4-carboxylic acid **31**, in which the C–Br bond is unactivated, failed to react with any β -diketone, even under forcing conditions. The arylpyranopyridinones **26b,c,e,f**, **40b,c,f** were converted to the arylnaphthyridinones **9b,c,e,f**, **11b,c,f** with ammonia in 2-methoxyethanol at elevated temperature and pressure.

Scheme 3 shows the synthetic approaches to the arylpyridinopyrimidinones. The most widely used route to the carbocyclic analogues, the 2-arylquinazolin-4-ones, is acylation of appropriately substituted anthranilamides at the amine nitrogen and base-catalysed cyclisation.⁴ However, in transferring this method to the arylpyridinopyrimidinones, all attempts to acylate aminopyridinecarboxamides with benzoyl chlorides failed. Liu *et al.* have reported an alternative access to quinazolinones through copper-catalysed reaction of benzamidines with 2-bromobenzoic acids.⁴⁵ Adapting this method to our targets would need a series of 4-substituted benzamidines **45** to provide diversity.

Following the route of Anbazhagan *et al.*,⁴⁶ attempts were made to convert the readily available 4-substituted benzonitriles **42** into the 4-substituted N-methoxybenzamidines **43**, prior to reduction of the N–O bond but the initial addition reaction failed for all but benzonitrile **42a** and the electron-poor 4-trifluoromethylbenzonitrile **42d**. However, the benzonitriles did react well with hydroxylamine to give the N-hydroxyamidines **44** in excellent yields for the electron-neutral and electron-deficient examples **42b,d,g,k,l** but failed wholly or partly for the less electrophilic compounds **42c** (0% yield) and **42g** (15%). Transfer hydrogenolysis using ammonium formate and Pd/C (Pt/C for the halo

9,26: b: R⁷ = 4-MePh; **c:** R⁷ = 4-MeOPh; **e:** R⁷ = 4-ClPh;
f: R⁷ = 4-BrPh
11,40: b: R³ = 4-MePh; **c:** R³ = 4-MeOPh; **f:** R³ = 4-BrPh
37: b: R = Me; **c:** R = OMe; **d:** R = CF₃; **e:** R = Cl; **f:** R = Br

Scheme 2. Syntheses of pyranopyridinones **26**, **40**, **41** and naphthyridinones **9**, **11** via Hurtley couplings or transition metal-free S_NAr reactions. *Reagents & conditions:* i, NaH, THF, Ar, 0°C, then reflux; ii, **37**, Cs₂CO₃, MeCN, reflux; iii, NH₃, MeO(CH₂)₂OH, pressure, 100°C; iv, **37a**, CuI, K₃PO₄, DMF, Ar, 100°C.

analogues **44e,f** furnished the amidines **45a,b,d-g,l**, with the nitro group of **44k** being reduced simultaneously to afford **45g**.

Cu(I)-catalysed cyclocondensation of benzamidines **45a,b,d** with 2-bromopyridine-3-carboxylic acid **38** afforded moderate yields of 2-arylpyrido[2,3-*d*]pyrimidin-4-ones **14a,b,d** and a low yield of the chloro analogue **14e** but the reaction failed for **45f,g,l**. Similar reactions of **45** with 4-bromopyridine-3-carboxylic acid **37**, where the C–Br is also activated, also gave good yields of **16a,b,d** and a low yield of **16e** and failed to provide **16f,g,l**. The isomeric 3-bromopyridine-4-carboxylic acid **31** was much less reactive, furnishing only **15a,b,d** in poor yields.

The amidines were also used in condensations with the cyclic β -keto ester **46** to provide the intermediate 6-benzyl-protected 2-aryl-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-ones **47**. Since the extended analogue **18j** was also required, 4-phenylethynylbenzamide **45j** was prepared in two steps (Sonogashira coupling of **42f** with phenylethyne and reaction of the intermediate **42j** with NaOMe and NH₄Cl). Condensation with **46** formed **47j** in good yield. From **47a,b,d,g**, the N-benzyl protection was removed by transfer hydrogenolysis under acidic conditions to give the target 2-aryl-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-ones **18a,b,d,g** in good yields. Interestingly, the alkyne of **47j** passed through this process unscathed to give **18j**.

2.3. Biochemical evaluation

Compounds were each initially screened at three different concentrations for inhibition of the catalytic activity of human TNKS-2 (automodification), using an assay previously developed by us.^{3,4} The data are expressed in Table 1 as percentage inhibition of enzyme activity, relative to control (no inhibitor). IC₅₀ values were measured for some selected analogues showing more

Scheme 3. Synthetic approaches to arylpyridopyrimidinones **14-16** and 2-aryl-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-ones **18**. *Reagents & conditions:* i, MeONH₂.HCl, Na₂CO₃, MeOH, H₂O (sonication for **42d**); ii, NH₂OH.HCl, NaHCO₃, EtOH, H₂O, reflux; iii, HCOONH₄, Pd/C (Pt/C for **46e,f**), AcOH, Ar, reflux; iv, **21a**, (Ph₃P)₄Pd, CuI, Na ascorbate, Pr₂NH, THF, Ar, 40°C; v, NH₄Cl, NaOMe, MeOH, reflux; vi, **45**, CuI, Cs₂CO₃, DMF, Ar, 80°C; vii, **45**, NaOMe, MeOH, reflux; viii, HCOOH, Pd/C, MeOH.

potency in the initial screen and for examples from each series (Table 2). These selected examples were also evaluated for inhibition of TNKS-1 (co-substrate = histone-1) and counterscreened

for isoform-selectivity using a PARP-1 inhibition assay, both as previously described.^{3,4}

Table 1. Initial screen of test compounds. Percentage inhibition of the catalytic activity of TNKS-2 by aryl-naphthyridinones, aryl-tetrahydronaphthyridinones, arylpyridopyrimidinones and aryl-tetrahydropyridopyrimidinones.

<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> 9-13, 29, 36 </div> <div style="text-align: center;"> 14-16 </div> <div style="text-align: center;"> 17 </div> <div style="text-align: center;"> 18, 49 </div> </div>							
Cpd.	X,Y,Z ^a	R	100 μM	10 μM	1.0 μM	100 nM	10 nM
9a	X = N	H			42 ± 4	0	0
9b	X = N	Me	97 ± 8	100	39 ± 3		
9c	X = N	OMe	93 ± 19	51 ± 22	0		
9d	X = N	CF ₃			14 ± 24	14 ± 10	1 ± 10
9e	X = N	Cl	100	96 ± 26	35 ± 25		
9f	X = N	Br		77 ± 8	47 ± 14	25 ± 4	
9g	X = N	NH ₂		96 ± 3	74 ± 5	0	
9i	X = N	OH		96 ± 5	58 ± 6	3 ± 13	
10a	Z = N	H			71 ± 8	18 ± 8	0
10b	Z = N	Me		85 ± 6	52 ± 20	0	
10c	Z = N	OMe			78 ± 3	31 ± 11	0

10g	Z = N	NH ₂			34 ± 15	14 ± 20	0
11b	Y = N	Me		92 ± 4	51 ± 8	13 ± 10	
11c	Y = N	OMe		97 ± 1	50 ± 13	9 ± 15	
11e	Y = N	Cl		84 ± 7	37 ± 15	0	
12a	X = N ⁺ -Me	H			0	24 ± 12	4 ± 10
12b	X = N ⁺ -Me	Me	100	100	83 ± 12		
12c	X = N ⁺ -Me	OMe		12 ± 5	9 ± 5	0	
12d	X = N ⁺ -Me	CF ₃			24 ± 4	0	
12e	X = N ⁺ -Me	Cl		9 ± 6	8 ± 10	17 ± 9	
12f	X = N ⁺ -Me	Br		45 ± 24	27 ± 5	23 ± 1	
12g	X = N ⁺ -Me	NH ₂		0	0	0	
13a	X = N ⁺ -O ⁻	H			23 ± 13	1 ± 6	0
13b	X = N ⁺ -O ⁻	Me		100	94 ± 2	12 ± 15	
14a	X = N	H	0	0	0		
14b	X = N	Me	71 ± 16	37 ± 20	17 ± 35		
14d	X = N	CF ₃		43 ± 9	20 ± 9	21 ± 37	
14e	X = N	Cl		15 ± 3	0	0	
15a	Z = N	H		80 ± 14	29 ± 6		
15b	Z = N	Me		93 ± 7	18 ± 18	0	
15d	Z = N	CF ₃		57 ± 6	19 ± 13	0	
16a	Y = N	H		15 ± 9	20 ± 4	0	
16b	Y = N	Me	86 ± 1	62 ± 11	43 ± 19		
16d	Y = N	CF ₃		65 ± 5	17 ± 14	0	
16e	Y = N	Cl		81 ± 9	9 ± 6	9 ± 4	
17a		H			99 ± 4	78 ± 3	43 ± 9
17c		OMe		100	82 ± 10	93 ± 15	
17d		CF ₃		95 ± 3	86 ± 5	82 ± 19	
17e		Cl		91 ± 14	89 ± 11	24 ± 12	
17f		Br		97 ± 3	89 ± 6	49 ± 7	
18a		R ² = Ph, R ⁶ = H		11 ± 14	0	0	
18b		R ² = 4-MePh, R ⁶ = H		35 ± 42	0	0	
18d		R ² = 4-F ₃ CPh, R ⁶ = H		7 ± 10	7 ± 11	19 ± 10	
18j		R ² = 4-PhC≡CPh, R ⁶ = H		36 ± 7	28 ± 9	0	
18l		R ² = pyridin-4-yl, R ⁶ = H		0	0	0	
29a	Z = N ⁺ -Me	H		0	14 ± 14	15 ± 5	
36c	Y = N ⁺ -Me	OMe		0	0	0	
47a		R ² = Ph, R ⁶ = Bn		0	0	0	
47b		R ² = 4-MePh, R ⁶ = Bn		0	0	0	
47d		R ² = 4-F ₃ CPh, R ⁶ = Bn		0	0	0	
47e		R ² = 4-ClPh, R ⁶ = Bn			18 ± 5	0	
47f		R ² = 4-BrPh, R ⁶ = Bn		0	0	0	
47j		R ² = 4-PhC≡CPh, R ⁶ = Bn		17 ± 15	7 ± 8	29 ± 20	
47l		R ² = pyridin-4-yl, R ⁶ = Bn		39 ± 9	0	0	

^a Positions not indicated are CH. ^b Unoccupied cells = not determined.

2.4. Structural studies

Compounds **12b** and **17a** were crystallised with TNKS-2 to rationalise the design of inhibitors and to understand their mode of binding (PDB codes 4W5I and 4UX4, respectively). Although TNKS-2 was used in the crystallographic studies, the catalytic domains of TNKS-1 and TNKS-2 are highly homologous and the residues at the inhibitor-binding sites are completely conserved. TNKS-2-inhibitor complexes were crystallised containing two monomers in the asymmetric unit. As the two monomers are almost identical, the discussion will refer to monomer A in both of the structures.

As expected, **12b** and **17a** bind to the nicotinamide-binding site of TNKS-2. The binding mode is typical of the PARP inhibitors, having the H-bonds to Gly¹⁰³² and Ser¹⁰⁶⁸ and the canonical stacking interaction with Tyr¹⁰⁷¹. This binding is shown in Figure 4 (B and C, respectively), with the corresponding structure of the isoquinolin-1-one **3** ($R^4 = \text{Me}$, $R^5 = \text{OMe}$) for comparison (Figure 4A).³ The binding mode of the compounds is almost identical, despite the differences in the *para*-substitution on the phenyl ring and the saturation state and charge of the heterocyclic system. When compared with the TNKS-2-nicotinamide complex (PDB code 3U9H),²⁹ both **12b** and **17a** induce a change in the side-chain of Phe¹⁰³⁵, which moves ~ 1.1 Å towards the *para*-position of the phenyl ring of the compounds. This may reflect the occupation of the hydrophobic cavity by the (substituted)phenyl of **12b** and **17a**, whereas this group is absent from the nicotinamide unit in NAD⁺.

2.5. Structure-activity relationships

Examining firstly the 7-aryl-1,6-naphthyridin-5-ones **9**, it is clear that the replacement of carbon-5 of the 5-arylisquinolin-1-ones **3** with nitrogen has a markedly deleterious effect on binding and potency. For example, **9a**, with a simple phenyl as the aryl group occupying the hydrophobic cavity, shows $\text{IC}_{50} = 5$ μM against TNKS-2 (Table 2), whereas the isoquinolinone analogue **3** ($R^4 = \text{H}$, $R^5 = \text{Me}$) has $\text{IC}_{50} = 1.8$ nM,⁴ indicating a loss of potency of some 1000-fold. The data from the initial three-concentration screen (Table 1) confirm that there is similar loss of activity (relative to **3**) for analogues with comparable *para*-substitution on the aryl group. The nature of the *para*-substituent is relatively unimportant within this series, with polar groups (in **9g,i**) conveying similar activity to non-polar groups (in **9b,e,f**). Interestingly, small electron-donating and electron-neutral groups are tolerated equally but an electron-withdrawing group (in **9d**) and a slightly longer group (in **9c**) reduce binding somewhat (Table 1). Moving the nitrogen to different positions in the naphthyridinone ring in **10** and **11** gives inhibitors of similar potency to **9** (Tables 1,2), *i.e.* 1000-fold loss of potency compared with the carbocyclic analogues **3**. In both **10** and **11**, the nature of the *para*-substituent on the phenyl is unimportant. Quaternisation of the ring-nitrogen in **12**, placing the methyl at the same position as in the highly potent 8-methylquinazolinones **2** and the 5-methylisoquinolinones **3** ($R^5 = \text{Me}$), led to complete inactivity, except in the case of the 4-methylphenyl example **12b**. Similarly, occupying the small binding pocket with oxygen in the N-oxide **13a** also diminished activity, although again the 4-methylphenyl analogue **13b** retained some binding. Moving the quaternised ⁺N-Me cation to other positions in the ring, in **29a** and **36c**, abolished activity. This is unsurprising on steric grounds, as the methyl groups in these latter two compounds would clash severely with the protein surface in this part of the binding site; compounds with substituents in this region are very poor inhibitors of many of the PARP isoforms.

Just as **9-11** are aza-analogues of the isoquinolinones **3**, pyridinopyrimidinones **14-16** are the aza-analogues of the quinazolinones **2**. There is also an approximately 1000-fold loss in potency in introducing the ring-nitrogen in these series (Table 1), compared with the parent quinazolinones **2**.³

Inhibition of the isoform TNKS-1 by **9a** and **10a** broadly followed the activity against TNKS-2 (Table 2). This is unsurprising, as their NAD⁺-binding domains have high homology. However, **11b** showed 17-fold selectivity for inhibition of TNKS-1 *vs.* TNKS-2 and is thus one of very few compounds to show this selectivity,² although several show selectivity towards TNKS-2.³

The dramatic loss in activity of the aryl naphthyridinones **9-11** and the arylpyridopyrimidinones **14-16**, compared with their carbocyclic equivalents **2** and **3**, appears to be consequent to electron-deficiency. Whereas the potency is diminished 1000-fold for the uncharged analogues **9-11**, **14-16**, relative to **2**, **3**, it is reduced further for the cationic compounds **12 a,c-g**. This observation is again consistent with electron-deficiency being deleterious to binding. A rationalisation may be an unfavourable interaction between the electron-poor rings and the positively charged side-chain ammonium of Lys¹⁰⁶⁷. As shown in crystal structures, this ammonium nitrogen is located only 5.5-6.0 Å from 1-N, 2-C and 3-C in **12b** (present work), whereas it is similarly located in the structure of the complex of **3** ($R^4 = \text{Me}$, $R^5 = \text{OMe}$) to make an attractive interaction with the electron-rich carbocyclic ring of this latter ligand (Figure 4).³ By contrast, the partly-saturated tetrahydropyridine rings of **17a-f**, active inhibitors of TNKS-2, are electron-rich and may also make attractive interactions with Lys¹⁰⁶⁷ (Figure 4).

Interestingly, the 7-aryl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-ones **17** showed interesting inhibitory activity (Table 2). Compounds **11a,c-f** all inhibited TNKS-2 with $\text{IC}_{50} < 100$ nM, with **17c,d** being more potent than XAV939 **1**.³ In this series, the *para*-substituent on the exocyclic phenyl ring had a marked effect on potency and isoform-selectivity. The parent **17a** had weaker and non-selective activity between the tankyrases. Analogues **17c** and **17d** (carrying OMe and CF₃ groups, respectively) were highly potent against both isoforms. Although the *para*-halo compounds **17e** and **17f** retained good potency against TNKS-2, they were much less active against TNKS-1, with **17f** being a potentially useful isoform-selective inhibitor of TNKS-2 (*ca.* 70-fold selectivity). The structural basis of the marked dependence of potency and selectivity on the nature of this *para*-substituent is unclear. What is clear is the close similarity of the conformation of **17**, as bound into TNKS-2, and the bound conformation of XAV939 **1**. Figure 5 shows **1** and **17a** as bound into TNKS-2, with the protein removed from the structure. This illustrates that both compounds adopt the same out-of-plane deformation of the (partly) saturated ring.

Compounds **18** and **47** are aza analogues of **1**, where the sulfur is replaced by a secondary amine (**18**) or a bulky tertiary amine (**47**). Both are strongly basic and would be expected to be protonated and cationic at physiological pH. As expected, the bulk of the benzyl group in this position in **47** abolishes binding and inhibitory activity (Table 1). Less expectedly, **18a,b,d,l** are also devoid of activity against TNKS-2, with **18j** (with the side-chain extension) showing only slight inhibition (36%) at 10 μM. Compound **18d** is the strict analogue of **1**, so the >1000-fold loss of activity is remarkable. Given the close similarity in structure between **18** and **1**, the loss of activity cannot be due to conformational issues or to steric clash. The major difference between **1** and **18** is that the neutral non-polar sulfur in the former is replaced by a polar cationic entity in the latter. The buckling of the saturated ring of **1** (Figure 5) places the sulfur in a relatively hyd-

Table 2. IC₅₀ values determined for inhibition of tankyrase-1, tankyrase-2 and PARP-1.

<div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;"> <p>9-11</p> </div> <div style="text-align: center;"> <p>17</p> </div> </div>					
Cpd.	X,Y,Z ^a	R	Tankyrase-1 IC ₅₀ (nM)	Tankyrase-2 IC ₅₀ (nM)	PARP-1 IC ₅₀ (nM)
1	[XAV939]		15 ± 4	15 ± 3	^b
9a	X = N	H	10.6 × 10 ³ ± 6.9 × 10 ³	5 × 10 ³ ± 1.1 × 10 ³	
10a	Z = N	H	2.2 × 10 ³ ± 0.2 × 10 ³	1.3 × 10 ³ ± 0.4 × 10 ³	
11b	Y = N	Me	350 ± 140	6.2 × 10 ³ ± 0.4 × 10 ³	43 × 10 ³ ± 2 × 10 ³
17a		H	189 ± 1	97 ± 35	949 ± 217
17c		OMe	1.7 ± 1.2	1.1 ± 0.4	3.4 × 10 ³ ± 1.0 × 10 ³
17d		CF ₃	7.5 ± 1.9	1.5 ± 0.4	4.8 × 10 ³ ± 1.6 × 10 ³
17e		Cl	134 ± 36	21 ± 1.4	2 × 10 ³
17f		Br	423 ± 256	6.1 ± 0.7	2 × 10 ³

^a Positions not indicated are CH. ^b Unoccupied cells = not determined.

rophobic region, bent away from the ammonium of Lys¹⁰⁶⁷.²⁵ Here the S is located 3.7 Å from the methyl of Ala¹⁰⁶² and immediately above the π -bond of the backbone amide carbonyl of Phe¹⁰⁶¹, placing it 4.2 Å from the γ -CH₂ of Lys¹⁰⁶⁷. The protonated cationic amine of **18** cannot make favourable interactions in this region. One may speculate that this unfavourable interaction is overcome to some extent by additional binding from the rigid linear phenylethynylphenyl unit in **18j** to give the observed modest inhibition; this extension would project into the narrow tunnel at the distal side of the hydrophobic cavity, by analogy with the potent TNKS-2 inhibitor **3** (R⁴ = -C≡CPh, R⁵ = Me).³

The potent inhibitors of TNKS-1 and TNKS-2, **17a,c-f**, were counterscreened for collateral inhibition of the superfamily member PARP-1 (Table 2). Only weak inhibition was observed in preliminary studies, indicating >1000-fold selectivity for the tankyrases for **17c,d**, in line with similar selectivities seen for quinazolinones **2** and isoquinolinones **3**.^{3,4}

2.6. Antiproliferative activity

Selected analogues showing inhibition of tankyrases were assessed for their antiproliferative activity against HT29 human colon carcinoma cells and against non-malignant FEK4 cells. The latter were isolated by Tyrrell from human foreskin and were a kind gift.⁴⁷ They were used as a model for normal tissue. The MTS assay was used, as previously reported by us.^{3,4} Most of the compounds examined did not inhibit the proliferation of either cell-type (Table 3). However, **11b** (a weak selective inhibitor of TNKS-1) had slight activity against HT29 cells. More striking was the selective toxicity of the 4'-halophenyl tetrahydronaphthyridinones **17e,f** towards the HT29 colon cancer cells, leaving the "normal" cells unscathed. Isoform-selectivity in inhibition of the tankyrases appears to correlate with selective anticancer cytotoxicity in this very preliminary study but there is, as yet, no evidence of a causal relationship.

Figure 4. Crystal structures of **12b** (B) and **17a** (C) bound into the nicotinamide-binding site and adjacent hydrophobic cavity of tankyrase-2. The corresponding structure of 5-methoxy-3-(4-methylphenyl)isoquinolin-1-one **3** (R⁴ = Me, R⁵ = OMe) bound into tankyrase-2 is shown for comparison (A).³ All three structures show the classical H-bonding motif of the lactam to Gly¹⁰³² and Ser¹⁰⁶⁸ and the proximity of the benzene (A), pyridinium (B) and tetrahydropyridine rings of the inhibitors to the ϵ -N⁺H₃ of Lys¹⁰⁶⁷.

Figure 5. Views of the structures of XAV939 **1** and **17a** as bound into tankyrase-2, showing similarity in conformation.

3. Conclusions

In this paper, we report the design of series of aryl-naphthyridinones and arylpyridopyrimidinones as aza analogues of 3-aryl-isoquinolin-1-ones **3** and 2-arylquinazolin-4-ones **2** (known potent and selective inhibitors),^{3,4} respectively, to test the tolerance

Table 3. Antiproliferative activities against HT29 human colon carcinoma cells and FEK4 human fibroblasts.

Cpd. No.	X,Y,Z ^a	R	HT29 IC ₅₀ (μM)	FEK4 IC ₅₀ (μM)
9a	X = N	H	>500 ^b	>500 ^b
10a	Z = N	H	>500 ^b	>500 ^b
11b	Y = N	Me	157 ± 88	>500 ^b
17a		H	>500 ^b	>500 ^b
17c		OMe	>200 ^b	>200 ^b
17d		CF ₃	>200 ^b	>200 ^b
17e		Cl	26 ± 5	>500 ^b
17f		Br	26 ± 5	>500 ^b

^a Positions not indicated are CH. ^b Limited by solubility.

of the inhibitor-binding motif of the tankyrases to the additional ring-nitrogen. These compounds were assembled by acid-catalysed cyclisation of the corresponding arylethynylpyridinenitriles to lactones and conversion to the naphthyridinones with ammonia. Methylation and oxidation took place at 1-N of 7-aryl-1,6-naphthyridin-5-ones, to introduce a small group in the region of space occupied by the C-Me in the potent 3-aryl-5-methylisoquinolin-1-ones and 2-aryl-8-methylquinazolin-4-ones.^{3,4} However, the electron-deficient pyridine ring in the naphthyridinones (replacing a benzene ring in the potent compounds) severely reduced binding and inhibitory potency, by up to three orders of magnitude. These results are rationalised by examining crystallographically the mode of binding of one analogue, **12b**. This compound makes the expected H-bonds with Gly¹⁰³² and Ser¹⁰⁶, with the benzene ring in the centre of the adjacent hydrophobic cavity; however, binding may be reduced by the proximity of the pyridine / pyridinium to the positively charged side-chain of Lys¹⁰⁶⁷. Examining more flexible analogues, the tetrahydropyridopyrimidines **18** are strict aza-analogues of the known inhibitor XAV939 (**1**)^{9,25} but replacement of lipophilic sulfur with (protonated) nitrogen abolished activity, owing to unfavourable interactions with the binding pocket, which is hydrophobic in this region. By contrast the 7-aryl-1-methyltetrahydronaphthyridinones **17** were highly potent for inhibition of the tankyrases. Interestingly, a crystal structure of **17a** bound into TNKS-2 revealed that it adopts the same buckle of the partly-saturated ring as does **1**.²⁵ Compounds **17** were also shown to be selective for the tankyrases, inhibiting PARP-1 only at μM concentrations.

These studies have allowed more definition of the structure-activity relationships for binding to and inhibiting the tankyrases, rationalised by structural understanding of the mode of binding. The identification of **17** as potent and selective inhibitors provides a new framework for design of improved agents and optimisation of pharmaceutical properties.

4. Experimental

4.1. Chemistry

Chemical reagents were purchased from Sigma Aldrich, Goss Scientific, Alfa Aesar and Fisher Scientific and were used as supplied. ¹H and ¹³C NMR spectra were recorded at 400.04 MHz

or 500.13 MHz (¹H) and 100.59 MHz or 125.76 MHz (¹³C), using (CD₃)₂SO containing SiMe₄, unless otherwise noted. Signals in ¹³C NMR spectra were assigned using HSQC and HMBC and signals in ¹⁵N spectra with HMBC. Reactions were monitored by thin-layer chromatography on silica gel 60Å (particle size 40–63 μm). MS data were obtained by electrospray ionisation using a microTOF MS (Bruker Daltonics, Germany) and were calibrated using HCO₂Na. Melting points were measured using a heated stage microscope (Reichert-Jung). Experiments were at ambient temperature, unless otherwise noted. Solutions in organic solvents were dried with MgSO₄. Experimental methods for the syntheses of **19h**, **20c-e,g,h,i**, **21c-e,g,i**, **24**, **31–34**, **37b-f,i**, **42j**, **43b,d**, **44d,d-g,k,l** and **45b,d-g,j,l** can be found in the Supplementary Information.

4.1.1. 7-Phenyl-1,6-naphthyridin-5-one (9a)

Compound **25a** (300 mg, 1.5 mmol) was stirred under reflux in aq. H₂SO₄ (9 M, 20 mL) for 1 h. After cooling, aq. NaOH (5 M) was added to pH 9. The mixture was extracted with EtOAc (5 × 25 mL). The combined extracts were dried. The evaporation residue was transferred into a pressure tube and dissolved in MeO(CH₂)₂OH (10 mL). NH₃ was passed through the solution until it was saturated, the vessel was closed and the mixture was heated at 100°C for 30 min. The mixture was cooled in ice and NH₃ was passed through again, followed by closure and heating (30 min). The cycle was repeated twice. Evaporation and recrystallisation (MeO(CH₂)₂OH) gave **9a** (249 mg, 75%) as a white solid: mp 226–230°C (lit.³⁰ mp 228–229°C); ¹H NMR δ 6.98 (1 H, s, 8-H), 7.54 (1 H, dd, *J* = 8.4, 4.9 Hz, 3-H), 7.57–7.60 (3 H, m, Ph 3,4,5-H₃), 7.89 (2 H, d, *J* = 7.9 Hz, Ph 2,6-H₂), 8.57 (1 H, dd, *J* = 8.0, 1.3 Hz, 4-H), 8.98 (1 H, dd, *J* = 4.5, 1.8 Hz, 2-H), 11.74 (br, NH); ¹³C NMR δ 104.56 (8-C), 120.40 (3-C), 121.62 (4a-C), 126.99 (Ph 3,5-C₂), 128.82 (Ph 2,6-C₂), 129.82 (Ph 4-C), 133.36 (Ph 1-C), 135.00 (4-C), 143.97 (7-C), 154.16 (2-C), 154.97 (8a-C), 162.93 (5-C); ¹⁵N NMR ((CD₃)₂SO) δ 124.89 (6-N), 278.87 (1-N), MS *m/z* 245.0676 (M + Na)⁺ (C₁₄H₁₀N₂NaO requires 245.0691).

4.1.2. 7-(4-Methylphenyl)-1,6-naphthyridin-5-one (9b)

Compound **25b** was treated with H₂SO₄, then NH₃, as for the synthesis of **9a**, to give **9b** (48%) as an off-white solid: mp 255–258°C; ¹H NMR δ 2.43 (3 H, s, Me), 6.95 (1 H, s, 8-H), 7.38 (2 H, d, *J* = 8.0 Hz, Ph 3,5-H₂), 7.54 (1 H, dd, *J* = 8.0, 4.5 Hz, 3-H), 7.79 (2 H, d, *J* = 8.2 Hz, Ph 2,6-H₂), 8.55 (1 H, ddd, *J* = 8.0, 1.6, 0.7 Hz, 4-H), 8.97 (1 H, dd, *J* = 4.5, 1.8 Hz, 2-H), 11.74 (1 H, br, NH); ¹³C NMR δ 20.81 (Me), 103.99 (8-C), 120.27 (4a-C), 121.43 (3-C), 126.82 (Ph 2,6-C₂), 129.38 (Ph 3,5-C₂), 130.54 (Ph 1-C), 134.97 (4-C), 139.60 (Ph 4-C), 144.01 (7-C), 154.27 (8a-C), 154.93 (2-C), 162.94 (5-C); MS *m/z* 259.0826 (M + Na)⁺ (C₁₅H₁₂N₂NaO requires 259.0847).

4.1.3. 7-(4-Methoxyphenyl)-1,6-naphthyridin-5-one (9c)

Compound **25c** was treated with H₂SO₄, then NH₃, as for the synthesis of **9a**, to give **9c** (70%) as an off-white solid: mp 276–280°C; ¹H NMR δ 3.89 (3 H, s, Me), 6.92 (1 H, s, 8-H), 7.12 (2 H, d, *J* = 8.9 Hz, Ph 3,5-H₂), 7.50 (1 H, dd, *J* = 8.0, 4.6 Hz, 3-H), 7.86 (2 H, d, *J* = 8.9 Hz, Ph 2,6-H₂), 8.54 (1 H, dd, *J* = 8.0, 1.8 Hz, 4-H), 8.95 (1 H, dd, *J* = 4.5, 1.8 Hz, 2-H), 11.65 (1 H, br, NH); ¹³C NMR δ 55.36 (Me), 114.24 (Ph 3,5-C₂), 120.01 (8-C), 122.42 (4a-C), 123.65 (Ph 1-C), 125.60 (3-C), 128.39 (Ph 2,6-C₂), 134.94 (7-C), 136.92 (4-C), 143.77 (2-C), 154.90 (8a-C), 156.99 (5-C), 158.82 (Ph 4-C); MS *m/z* 275.0767 (M + Na)⁺ (C₁₅H₁₂N₂NaO₂ requires 275.0796), 253.0978 (M + H)⁺ (C₁₅H₁₃N₂O₂ requires 253.0977).

4.1.4. 7-(4-Trifluoromethylphenyl)-1,6-naphthyridin-5-one (9d)

Compound **25d** was treated with H₂SO₄, then NH₃, as for the synthesis of **9a**, to give **9d** (55%) as a white solid: mp >325°C; ¹H NMR δ 7.03 (1 H, s, 8-H), 7.53 (1 H, dd, *J* = 8.0, 4.6 Hz, 3-H), 7.92 (2 H, d, *J* = 8.4 Hz, Ph 3,5-H₂), 8.10 (2 H, d, *J* = 8.2 Hz, Ph 2,6-H₂), 8.53 (1 H, dd, *J* = 8.0, 1.7 Hz, 4-H), 9.00 (1 H, dd, *J* = 4.5, 1.8 Hz, 2-H), 11.25 (1 H, br, NH); ¹³C NMR 105.92 (8-C), 120.90 (4a-C), 122.13 (3-C), 124.1 (q, *J* = 264 Hz, CF₃), 125.62 (q, *J* = 3.6 Hz, Ph 3,5-C₂), 128.03 (Ph 2,6-C₂), 129.78 (q, *J* = 32 Hz, Ph 4-C), 135.05 (4-C), 137.31 (Ph 1-C), 142.51 (7-C), 153.90 (2-C), 155.09 (8a-C), 162.86 (5-C); ¹⁵N NMR δ 123.4 (6-N), 279.7 (1-N); ¹⁹F NMR δ -61.20 (s, CF₃); MS *m/z* 291.0727 (M + H)⁺ (C₁₅H₁₀N₂O requires 291.0745).

4.1.5. 7-(4-Chlorophenyl)-1,6-naphthyridin-5-one (9e)

Compound **25e** was treated with H₂SO₄, then NH₃, as for the synthesis of **9a**, to give **9d** (33%) as an off-white solid: mp 296–298°C; IR ν_{max} 3163, 1669, 1627, 1588, 720 cm⁻¹; ¹H NMR δ 6.95 (1 H, s, 8-H), 7.50 (1 H, dd, *J* = 8.0, 4.5 Hz, 3-H), 7.58 (2 H, d, *J* = 9.0 Hz, Ph 3,5-H₂), 7.91 (2 H, d, *J* = 8.5 Hz, Ph 2,6-H₂), 8.51 (1 H, d, *J* = 8.0 Hz, 4-H), 8.98 (1 H, d, *J* = 4.5 Hz, 2-H), 11.74 (1 H, br, NH); ¹³C δ 104.95 (8-C), 120.58 (4a-C), 121.83 (3-C), 128.82 (Ph 3,5-C₂), 128.93 (Ph 2,6-C₂), 134.60 (4-C), 135.03 (Ph 1-C), 155.05 (C=O), 162.90 (8a-C); ¹⁵N NMR (HMBC) δ 124.20 (s, 6-N); MS *m/z* 279.0278 (M + Na)⁺ (C₁₄H₉³⁵ClN₂NaO requires 279.0296), 259.0420 (M + H)⁺ (C₁₄H₁₀³⁷ClN₂O requires 259.0450), 257.0482 (M + H)⁺ (C₁₄H₁₀³⁵ClN₂O requires 257.0476).

4.1.6. 7-(4-Bromophenyl)-1,6-naphthyridin-5-one (9f)

NH₃ was bubbled through **26f** (140 mg, 0.47 mmol) in MeO(CH₂)₂OH (10 mL) for 10 min in a pressure vessel. The vessel was closed and the mixture was heated at 120°C for 30 min. The reaction mixture was cooled in ice and NH₃ was bubbled again, followed by closure and heating (30 min). The cycle was repeated twice. Evaporation and recrystallisation (EtOH) gave **9f** (100 mg, 75%) as a buff powder: mp 304–305°C; ¹H NMR δ 7.05 (1 H, s, 8-H), 7.50 (1 H, dd, *J* = 7.7, 4.0 Hz, 3-H), 7.39 (2 H, d, *J* = 8 Hz, Ph 3,5-H₂), 7.84 (2 H, d, *J* = 8 Hz, Ph 2,6-H₂), 8.30 (1 H, d, *J* = 7.7 Hz, 4-H), 8.69 (1 H, d, *J* = 4.8 Hz, 2-H), 9.15 (1 H, br, NH); ¹³C NMR δ 105.80 (8-C), 122.51 (4a-C), 122.97 (Ph 4-C), 123.61 (3-C), 127.41 (Ph 1-C), 130.22 (Ph 2,6-C₂), 130.75 (Ph 3,5-C₂), 131.91 (7-C), 134.61 (4-C), 156.71 (8a-C), 168.09 (5-C); MS *m/z* 627 / 625 / 623 (2 M + Na)⁺, 324.9771 (M + Na)⁺ (C₁₄H₉⁸¹BrN₂NaO requires 324.9774), 322.9790 (M + Na)⁺ (C₁₄H₉⁷⁹BrN₂NaO requires 322.9805), 302.9964 (M + H)⁺ (C₁₄H₁₀⁸¹BrN₂O requires 302.9951), 301.0024 (M + H)⁺ (C₁₄H₁₀⁷⁹BrN₂O requires 300.9971).

4.1.7. 7-(4-Aminophenyl)-1,6-naphthyridin-5-one (9g)

Compound **26g** was treated with H₂SO₄, then NH₃, as for the synthesis of **9a**, to give **9g** (66%) as a yellow powder: mp >300°C; ¹H NMR δ 5.65 (2 H, br, NH₂), 6.80 (1 H, s, 8-H), 7.43 (1 H, dd, *J* = 8.0, 4.5 Hz, 3-H), 7.60 (2 H, d, *J* = 8.6 Hz, Ph 3,5-H₂), 7.71 (2 H, d, *J* = 8.7 Hz, Ph 2,6-H₂), 8.49 (1 H, dd, *J* = 8.0, 1.8 Hz, 4-H), 8.90 (1 H, dd, *J* = 4.8, 1.8 Hz, 2-H), 11.50 (1 H, br, NH); ¹³C NMR δ 99.08 (8-C), 113.59 (Ph 3,5-C₂), 117.55 (3-C), 122.16 (4a-C), 124.87 (Ph 1-C), 127.78 (4-C), 130.51 (Ph 2,6-C₂), 136.95 (7-C), 150.62 (2-C), 153.57 (Ph 4-C), 156.59 (8a-C), 161.65 (5-C).

4.1.8. 7-(4-Hydroxyphenyl)-1,6-naphthyridin-5-one (9i)

Compound **25h** was treated with H₂SO₄, then NH₃, as for the synthesis of **9a**, to give **9i** (10%) as a pale buff solid: mp 258–260°C; IR ν_{max} 3423, 1660, 1617, 1589 cm⁻¹; ¹H NMR δ 6.87 (1 H, s, 8-H), 6.93 (2 H, d, *J* = 8.6 Hz, Ph 2,6-H₂), 7.37 (1 H, d, *J* = 7.4 Hz, 3-H), 7.73 (2 H, d, *J* = 8.6 Hz, Ph 3,5-H₂), 8.52 (1 H, d, *J*

= 2.5 Hz, 4-H), 8.94 (1 H, d, *J* = 2.5 Hz, 2-H), 9.99 (1 H, br, OH), 11.67 (1 H, br, NH); ¹³C NMR δ 115.57 (8-C), 119.0 (3-C), 121.0 (Ph 1-C), 126.0 (4a-C), 128.11 (Ph 2,6-C₂), 128.42 (Ph 3,5-C₂), 135.0 (4-C), 147.0 (2-C), 153.0 (Ph 4-C), 154.89 (8a-C), 163.0 (5-C); MS *m/z* 239.0816 (M + H)⁺ (C₁₄H₁₁N₂O₂ requires 239.0816); MS *m/z* 237.0632 (M - H)⁻ (C₁₄H₉N₂O₂ requires 237.0659).

4.1.9. 3-Phenyl-2,6-naphthyridin-1-one (10a)

Compound **35a** (100 mg, 0.49 mmol) was stirred at 120°C in polyphosphoric acid (10 mL) for 1 h. After cooling, aq. NaOH (5 M) was added to pH 8. The mixture was extracted (EtOAc, 3×). The combined extracts were dried. The evaporation residue was transferred into a pressure tube and dissolved in MeO(CH₂)₂OH (5 mL). NH₃ was bubbled through the solution, the vessel was closed and the mixture was heated at 130°C for 30 min. The reaction mixture was cooled in ice and NH₃ was bubbled again, followed by closure and heating (30 min). The cycle was repeated thrice. Evaporation and trituration (EtOH) gave an inseparable mixture of **10a** and **32** (85 mg) as a gum. ¹H NMR showed that the mixture comprised **10a** (56% yield) and **32** (22% yield). **10a**: ¹H NMR δ 7.11 (1 H, s, 4-H), 7.39 (1 H, m, Ph 4-H), 7.42 (2 H, m, Ph 3,5-H₂), 7.67 (2 H, d, *J* = 7.0 Hz, Ph 2,6-H₂), 8.64 (1 H, s, 8-H), 8.70 (1 H, s, 7-H), 8.99 (1 H, s, 5-H), 11.68 (1 H, br, NH); ¹³C NMR δ 101.50 (4-C), 121.20 (8-C), 125.50 (m, Ph 3,4,5-C₃), 128.50 (Ph 2,6-C₂), 131.00 (Ph 1-C), 132.90 (8a-C), 146.50 (7-C), 151.50 (5-C); MS *m/z* 223.0875 (M + H)⁺ (C₁₄H₁₁N₂O requires 223.0866). **32**: ¹H NMR δ 7.10 (1 H, s, 4-H), 7.86 (2 H, d, *J* = 8.2 Hz, Ph 2,6-H₂), 7.98–8.00 (3 H, m, Ph 3,4,5-H₃), 8.08 (1 H, d, *J* = 5.2 Hz, 8-H), 8.67 (1 H, d, *J* = 5.3 Hz, 7-H), 9.17 (1 H, s, 5-H); ¹³C NMR δ 98.52 (4-C), 118.0 (8-C), 125.42 (Ph 2,6-C₂), 127.00 (8a-C), 129.01 (Ph 3,5-C₂), 130.64 (Ph 4-C), 131.20 (Ph 1-C), 132.00 (3-C), 148.44 (7-C), 149.00 (5-C), 151.00 (1-C); MS *m/z* 245 (M + Na), 223.0875 (M + H)⁺ (C₁₄H₁₁N₂O requires 223.0866).

4.1.10. 3-(4-Methylphenyl)-2,6-naphthyridin-1-one (10b)

Compound **35b** was treated with polyphosphoric acid, then with NH₃, as for the synthesis of **10a**, except that the product was recrystallised (EtOH) to give **10b** (6%) as an off-white solid: mp 188–189°C; ¹H NMR δ 7.07 (1 H, s, 4-H), 7.38 (2 H, d, *J* = 7.9 Hz, Ph 3,5-H₂), 7.76 (2 H, d, *J* = 8.2 Hz, Ph 2,6-H₂), 8.04 (1 H, d, *J* = 5.3 Hz, 8-H), 8.66 (1 H, d, *J* = 5.3 Hz, 7-H), 9.15 (1 H, d, *J* = 0.8 Hz, 5-H), 11.90 (1 H, br, NH); ¹³C NMR δ 20.70 (Me), 100.10 (4-C), 119.80 (8-C), 127.10 (Ph 2,6-C₂), 129.53 (Ph 3,5-C₂), 146.20 (7-C), 148.90 (5-C); MS *m/z* 495.1796 (2 M + Na)⁺ (C₃₀H₂₄N₄NaO₂ requires 495.1797), 259.0834 (M + Na)⁺ (C₁₅H₁₂N₂NaO requires 259.0847), 237.1022 (M + H)⁺ (C₁₅H₁₃N₂O requires 237.1028).

4.1.11. 3-(4-Methoxyphenyl)-2,6-naphthyridin-1-one (10c)

Compound **35c** was treated with polyphosphoric acid, then NH₃, as for the synthesis of **10b**, to give **10c** (37%) as an off-white solid: mp 244–245°C; ¹H NMR δ 3.90 (3 H, s, Me), 7.11 (1 H, s, 4-H), 7.12 (2 H, d, *J* = 8.4 Hz, Ph 3,5-H₂), 7.63 (2 H, d, *J* = 8.9 Hz, Ph 2,6-H₂), 7.80 (1 H, d, *J* = 5.1 Hz, 8-H), 8.83 (1 H, d, *J* = 5.1 Hz, 7-H), 9.04 (1 H, s, 5-H); ¹³C NMR δ 55.54 (Me), 113.87 (Ph 3,5-C₂), 114.74 (4-C), 121.10 (4a-C), 124.89 (8-C), 130.32 (Ph 2,6-C₂), 131.82 (Ph 1-C), 134.20 (8a-C), 135.10 (3-C), 149.01 (7-C), 152.10 (5-C), 160.42 (1-C), 160.99 (Ph 4-C); MS *m/z* 527.1679 (2 M + Na)⁺ (C₃₀H₂₄N₄NaO₄ requires 527.1695), 275.0772 (M + Na)⁺ (C₁₅H₁₂N₂NaO₂ requires 275.0796), 253.0960 (M + H)⁺ (C₁₅H₁₃N₂O₂ requires 253.0977).

4.1.12. 3-(4-Chlorophenyl)-2,6-naphthyridin-1-one (10e)

Compound **35e** was treated with polyphosphoric acid, then NH₃, as for the synthesis of **10b**, to give **10e** (27%) as an off-white solid: mp 257–259°C; ¹H NMR δ 7.12 (1 H, s, 4-H), 7.64

(2 H, d, $J = 8.7$ Hz, Ph 3,5- H_2), 7.88 (2 H, d, $J = 8.6$ Hz, Ph 2,6- H_2), 8.05 (1 H, d, $J = 5.3$ Hz, 8-H), 8.69 (1 H, d, $J = 5.3$ Hz, 7-H), 9.17 (1 H, s, 5-H), 11.75 (1 H, br, NH); ^{13}C NMR δ 101.92 (4-C), 119.10 (8-C), 128.73 (Ph 2,6- C_2), 128.82 (Ph 3,5- C_2), 130.01 (4a-C), 132.05 (Ph 1-C), 134.10 (Ph 4-C), 137.10 (8a-C), 142.00 (3-C), 146.53 (7-C), 150.20 (5-C), 156.31 (1-C); MS m/z 279 ($M + \text{Na}$) $^+$, 257.0475 ($M + \text{H}$) $^+$ ($\text{C}_{14}\text{H}_{10}^{35}\text{ClN}_2\text{O}$ requires 257.0482).

4.1.13. 3-Phenyl-2,7-naphthyridin-1-one (11a)

Compound **28a** (300 mg, 1.5 mmol) was stirred under reflux in aq. H_2SO_4 (9 M, 20 mL) for 1 h. After cooling, aq. NaOH (5 M) was added to pH 9. The mixture was extracted with EtOAc (5 $\times$ 25 mL). The evaporation residue was transferred into a pressure tube and dissolved in $\text{MeO}(\text{CH}_2)_2\text{OH}$ (10 mL). NH_3 was passed through the solution, the vessel was closed and the mixture was heated at 100°C for 30 min. The reaction mixture was cooled in ice and NH_3 was passed through again, followed by closure and heating (30 min). The cycle was repeated twice. Evaporation and recrystallisation ($\text{MeO}(\text{CH}_2)_2\text{OH}$) gave **11a** (131 mg, 40%) as an off-white solid: mp 236–237°C (lit.³⁴ 237–238°C); IR ν_{max} 3447, 1669, 1631, 1595, 1461 cm^{-1} ; ^1H NMR δ 6.97 (1 H, s, 4-H), 7.58 (3 H, m, Ph 3,4,5- H_3), 7.66 (1 H, d, $J = 5.4$ Hz, 5-H), 7.86 (2 H, dd, $J = 7.6$ Hz, Ph 2,6- H_2), 8.76 (1 H, d, $J = 5.4$ Hz, 6-H), 9.38 (1 H, s, 8-H), 11.91 (1 H, br, NH); ^{13}C NMR δ 101.41 (4-C), 119.66 (5-C), 127.12 (Ph 2,6- C_2), 128.87 (Ph 3,5- C_2), 130.14 (Ph 4-C), 133.26 (Ph 1-C), 143.11 (4a-C), 145.27 (8a-C), 149.84 (8-C), 150.98 (6-C), 162.37 (1-C); MS m/z 223.0866 ($M + \text{H}$) $^+$ ($\text{C}_{14}\text{H}_{11}\text{N}_2\text{O}$ requires 223.0935).

4.1.14. 3-(4-Methylphenyl)-2,7-naphthyridin-1-one (11b)

NH_3 was bubbled through **40b** (35 mg, 0.15 mmol) in $\text{MeO}(\text{CH}_2)_2\text{OH}$ (10 mL) for 10 min in a pressure vessel. The vessel was closed and the mixture was heated at 120°C for 30 min. The reaction mixture was cooled in ice and NH_3 was bubbled again, followed by closure and heating (30 min). The cycle was repeated twice. Evaporation and recrystallisation (EtOH) gave **11b** (12 mg, 31%) as an off-white powder: mp > 300°C (decomp.); ^1H NMR δ 2.43 (3 H, s, Me), 6.94 (1 H, s, 4-H), 7.38 (2 H, d, $J = 8.1$ Hz, Ph 3,5- H_2), 7.63 (1 H, d, $J = 5.6$ Hz, 5-H), 7.77 (2 H, d, $J = 8.2$ Hz, Ph 2,6- H_2), 8.73 (1 H, d, $J = 5.5$ Hz, 6-H), 9.36 (1 H, s, 8-H), 11.70 (1 H, br, NH); ^{13}C NMR δ 21.16 (Me), 100.79 (4-C), 119.55 (8a-C), 127.40 (Ph 2,6- C_2), 128.67 (5-C), 129.38 (Ph 3,5- C_2), 129.40 (Ph 1-C), 144.10 (Ph 4-C), 145.23 (4a-C), 146.00 (3-C), 150.88 (8-C), 153.00 (6-C), 162.36 (1-C); MS m/z 495 (2 $M + \text{Na}$) $^+$, 259.0841 ($M + \text{Na}$) $^+$ ($\text{C}_{15}\text{H}_{12}\text{N}_2\text{NaO}$ requires 259.0842).

4.1.15. 3-(4-Methoxyphenyl)-2,7-naphthyridin-1-one (11c)

Compound **28c** was treated with H_2SO_4 , then NH_3 , as for the synthesis of **11a**, to give **11c** (32%) as a pale orange solid: mp > 300°C (decomp.); ^1H NMR δ 3.89 (3 H, s, Me), 6.90 (1 H, s, 4-H), 7.13 (2 H, d, $J = 8.5$ Hz, Ph 3,5- H_2), 7.62 (1 H, d, $J = 8.9$ Hz, 5-H), 7.84 (2 H, d, $J = 9.0$ Hz, Ph 2,6- H_2), 8.72 (1 H, d, $J = 5.4$, 1.3 Hz, 6-H), 9.35 (1 H, s, 8-H), 11.82 (1 H, br, NH); ^{13}C NMR δ 55.41 (Me), 100.15 (4-C), 114.27 (Ph 3,5- C_2), 119.34 (4a-C), 119.44 (5-C), 125.39 (Ph 1-C), 128.54 (Ph 2,6- C_2), 143.26 (8a-C), 145.02 (3-C), 149.80 (8-C), 150.84 (6-C), 160.78 (Ph 4-C), 162.40 (1-C); MS m/z 253.0985 ($M + \text{Na}$) $^+$ ($\text{C}_{15}\text{H}_{13}\text{N}_2\text{O}_2$ requires 253.0972).

4.1.16. 3-(4-Aminophenyl)-2,7-naphthyridin-1-one (11g)

Compound **28g** (40 mg, 0.18 mmol) was stirred under reflux in aq. H_2SO_4 (9 M, 20 mL) for 1 h. After cooling, aq. NaOH (5 M) was added to pH 9. The mixture was extracted (EtOAc, 5 $\times$ 25 mL). Aq. HCl (9 M) was added to the aqueous layer to pH 1. The latter was washed thrice with EtOAc. The solution was basified with aq. NaOH (5 M) to pH 9 and extracted with EtOAc (5 $\times$). The extracts were dried. Evaporation and recrystallisation

(EtOAc) gave **11g** (15 mg, 36%) as a white solid: mp 235–236°C; IR ν_{max} 3172, 1669, 1617, 1594 cm^{-1} ; ^1H NMR δ 5.71 (2 H, br, NH_2), 6.69 (2 H, dd, $J = 8.8$ Hz, Ph 3,5- H_2), 6.77 (1 H, s, 4-H), 7.54 (1 H, d, $J = 5.7$ Hz, 5-H), 7.59 (2 H, d, $J = 8.8$ Hz, Ph 2,6- H_2), 8.65 (1 H, d, $J = 5.4$ Hz, 6-H), 9.28 (1 H, s, 8-H), 11.74 (1 H, br, NH); ^{13}C NMR δ 97.99 (4-C), 112.43 (Ph 1-C), 113.48 (3,5- C_2), 199.10 (5-C), 127.96 (2,6- C_2), 130.41 (3-C), 143.56 (4a-C), 145.99 (8a-C), 150.55 (8-C), 150.91 (6-C), 152.0 (Ph 4-C), 162.46 (1-C); MS m/z 238.0950 ($M + \text{H}$) $^+$ ($\text{C}_{14}\text{H}_{12}\text{N}_3\text{O}$ requires 238.0975).

4.1.17. 1-Methyl-5-oxo-7-phenyl-1,6-naphthyridinium iodide (12a)

MeI (410 mg, 2.9 mmol) was stirred with **9a** (120 mg, 0.54 mmol) in dry DMF (5 mL) for 36 h. The mixture was poured into Me_2CO (3 mL). The solid was collected, washed (Me_2CO) and dried to give **12a** (142 mg, 72%) as a yellow solid: mp 280–284°C, ^1H NMR δ 4.40 (3 H, s, Me), 7.18 (1 H, s, 8-H), 7.63 (3 H, m, Ph 3,4,5- H_3), 7.88 (1 H, dd, $J = 8.0$, 6.0 Hz, 3-H), 7.98 (2 H, d, $J = 7.5$ Hz, Ph 2,6- H_2), 9.09 (1 H, d, $J = 7.5$ Hz, 4-H), 9.20 (1 H, d, $J = 5.5$ Hz, 2-H), 12.87 (1 H, s, 6-H); ^{13}C NMR δ 44.97 (Me), 93.61 (8-C), 121.24 (3-C), 123.03 (4a-C), 128.05 (Ph 2,6- C_2), 128.98 (Ph 3,5- C_2), 131.55 (Ph 4-C), 132 (Ph 1-C), 144.13 (4-C), 147.98 (8a-C), 150.91, 153 (7-C), 161 (5-C); MS m/z 237.1012 (M) $^+$ ($\text{C}_{15}\text{H}_{13}\text{N}_2\text{O}$ requires 237.1022).

4.1.18. 1-Methyl-7-(4-methylphenyl)-5-oxo-1,6-naphthyridin-1-ium iodide (12b)

Compound **9b** was treated with MeI, as for the synthesis of **12a**, to give **12b** (64%) as a yellow solid: mp 273–276°C; IR ν_{max} 3431, 3250, 1665, 1606, 1507 cm^{-1} ; ^1H NMR δ 2.41 (3 H, s, PhMe), 4.38 (3 H, s, NMe), 7.13 (1 H, s, 8-H), 7.40 (2 H, d, $J = 8.0$ Hz, Ph 3,5- H_2), 7.82 (1 H, m, 3-H), 7.92 (2 H, d, $J = 8.0$ Hz, Ph 2,6- H_2), 9.04 (1 H, d, $J = 8.0$ Hz, 4-H), 9.16 (1 H, br, 2-H); ^{13}C NMR δ 20.99 (PhMe), 44.80 (NMe), 92.55 (8-C), 120.59 (3-C), 122.78 (4a-C), 127.91 (Ph 2,6- C_2), 129.43 (Ph 1-C), 129.52 (Ph 3,5- C_2), 141.69 (Ph 4-C), 143.98 (4-C), 148.05 (8a-C), 150.55 (2-C), 153.5 (br, 7-C); ^{15}N NMR δ 155.00 (1-N); MS m/z 251.1175 (M) $^+$ ($\text{C}_{16}\text{H}_{15}\text{N}_2\text{O}$ requires 251.1179).

4.1.19. 7-(4-Methoxyphenyl)-1-methyl-5-oxo-1,6-naphthyridin-1-ium iodide (12c)

MeI (144 mg, 1.0 mmol) was stirred with **9c** (76 mg, 0.3 mmol) in dry DMF (5 mL) for 3 d. The mixture was poured into EtOAc (25 mL) and petroleum ether (25 mL). The solid was collected, washed (petroleum ether) and dried to give **12c** (5.0 mg, 4%) as a yellow solid: mp > 300°C (decomp.); ^1H NMR δ 3.94 (3 H, s, OMe), 4.46 (3 H, s, NMe), 7.19 (1 H, s, 8-H), 7.22 (2 H, d, $J = 8.9$ Hz, Ph 3,5- H_2), 7.93 (1 H, dd, $J = 8.0$, 6.2 Hz, 3-H), 8.04 (2 H, d, $J = 8.9$ Hz, Ph 2,6- H_2), 9.13 (1 H, d, $J = 7.5$ Hz, 4-H), 9.25 (1 H, d, $J = 6.3$ Hz, 2-H), 12.77 (1 H, br, NH); ^{13}C NMR δ 44.0 (NMe), 57.0 (OMe), 127.0 (Ph 2,6- C_2), 132.0 (Ph 3,5- C_2), 148.0 (4-C); MS m/z 267.1136 (M) $^+$ ($\text{C}_{16}\text{H}_{15}\text{N}_2\text{O}_2$ requires 267.1134).

4.1.20. 1-Methyl-5-oxo-7-(4-trifluoromethylphenyl)-1,6-naphthyridin-1-ium iodide (12d)

Compound **9d** (30 mg, 0.21 mmol) was stirred with MeI (90 mg, 0.63 mmol) in dry DMF (5 mL) for 72 h. The mixture was poured into EtOAc (3 mL). The solid was collected, washed (EtOAc) and dried to give **12d** (40 mg, 90%) as a yellow solid. mp 298–299°C; ^1H NMR δ 4.45 (3 H, s, Me), 7.31 (1 H, s, 8-H), 7.59 (1 H, m, 3-H), 7.99 (2 H, d, $J = 8.8$ Hz, Ph 2,6- H_2), 8.17 (2 H, d, $J = 6.4$ Hz, Ph 3,5- H_2), 9.15 (1 H, d, $J = 6.4$ Hz, 4-H), 9.30 (1 H, d, $J = 4.4$ Hz, 2-H), 13.00 (1 H, br, NH); ^{13}C NMR δ 45.34 (Me), 95.52 (8-C), 122.44 (3-C), 123.64 (4a-C), 124.94 (q, $J = 271.0$ Hz, CF_3), 125.81 (q, $J = 3.6$ Hz, Ph 3,5- C_2), 129.21 (Ph 2,6- C_2), 131.16 (q, $J = 34.0$ Hz, Ph 4-C), 136.15 (7-C), 144.30

(3-C), 147.81 (8a-C), 149.89 (Ph 1-C), 151.41 (2-C), 160.46 (1-C); ^{19}F NMR ($(\text{CD}_3)_2\text{SO}$) δ -61.35 (s, CF_3); MS m/z 305.0895 (M) $^+$ ($\text{C}_{16}\text{H}_{12}\text{F}_3\text{N}_2\text{O}$ requires 305.0896).

4.1.21. 7-(4-Chlorophenyl)-1-methyl-5-oxo-1,6-naphthyridin-1-ium iodide (**12e**)

MeI (226 mg, 1.6 mmol) was stirred with **9e** (78 mg, 0.3 mmol) in dry DMF (5 mL) for 4 d. The evaporation residue was washed (EtOAc, petroleum ether) and dried to give **12e** (20 mg, 16%) as a yellow solid: mp >300°C (decomp.); ^1H NMR δ 4.42 (3 H, s, Me), 7.26 (1 H, s, 8-H), 7.84 (1 H, dd, J = 6.5, 5.8 Hz, 3-H), 7.99 (2 H, d, J = 8.3 Hz, Ph 2,6- H_2), 8.31 (2 H, d, J = 8.2 Hz, Ph 3,5- H_2), 9.07 (1 H, d, J = 6.5 Hz, 4-H), 9.18 (1 H, d, J = 5.8 Hz, 2-H), 12.53 (1 H, br, NH); ^{13}C NMR δ 48.56 (Me), 90.0 (8-C), 118.0 (3-C), 127.0 (Ph 2,6- C_2), 130.0 (Ph 3,5- C_2), 151.0 (2-C); MS m/z 273.0626 (M) $^+$ ($\text{C}_{15}\text{H}_{12}^{37}\text{ClN}_2\text{O}$ requires 273.0608); 271.0634 (M) $^+$ ($\text{C}_{15}\text{H}_{12}^{35}\text{ClN}_2\text{O}$ requires 271.0638).

4.1.22. 7-(4-Bromophenyl)-1-methyl-5-oxo-1,6-naphthyridin-1-ium iodide (**12f**)

Compound **9f** was treated with MeI, as for the synthesis of **12a**, to give **12f** (52%) as a yellow solid: mp 292-294°C, ^1H NMR δ 4.48 (3 H, s, Me), 7.29 (1 H, s, 8-H), 7.89 (2 H, d, J = 8.7 Hz, Ph 2,6- H_2), 7.97 (1 H, m, 3-H), 7.98 (2 H, d, J = 8.7 Hz, Ph 3,5- H_2), 9.18 (1 H, d, J = 7.9 Hz, 4-H), 9.30 (1 H, d, J = 5.8 Hz, 2-H), 12.94 (1 H, s, NH); ^{13}C NMR δ 45.98 (Me), 95.00 (8-C), 122.40 (3-C), 123.00 (4a-C), 126.00 (Ph 4-C), 130.12 (Ph 2,6- C_2), 130.50 (Ph 1-C), 131.98 (Ph 3,5- C_2), 132.55 (3-C), 144.50 (4-C), 148.50 (8a-C), 152.50 (2-C), 155.5 (1-C); MS m/z 317.0108 (M) $^+$ ($\text{C}_{15}\text{H}_{12}^{81}\text{BrN}_2\text{NaO}$ requires 317.0221), 315.0128 (M) $^+$ ($\text{C}_{15}\text{H}_{12}^{79}\text{BrN}_2\text{NaO}$ requires 315.0110).

4.1.23. 7-(4-Aminophenyl)-1-methyl-5-oxo-1,6-naphthyridin-1-ium iodide (**12g**)

MeI (144 mg, 1.02 mmol) was stirred with **9g** (42 mg, 0.19 mmol) in dry DMF (5 mL) for 4 d at room temperature, then at 80°C for 2 h. The mixture was poured into EtOAc (25 mL) and petroleum ether (25 mL). The solid was collected, washed (petroleum ether) and dried to give **12g** (28 mg, 41%) as a yellow solid: mp >300°C (decomp.); IR ν_{max} 3431, 3212, 1666, 1593, 1565 cm^{-1} ; ^1H NMR δ 4.40 (3 H, s, Me), 6.89 (2 H, d, J = 9.0 Hz, Ph 3,5- H_2), 7.08 (1 H, s, 8-H), 7.78 (1 H, dd, J = 7.8, 6.2 Hz, 3-H), 7.98 (2 H, d, J = 9.1 Hz, Ph 2,6- H_2), 9.03 (1 H, d, J = 7.8 Hz, 4-H), 9.14 (1 H, d, J = 5.2 Hz, 2-H), 12.53 (1 H, br, NH); ^{13}C NMR δ 44.73 (Me), 90.53 (8-C), 111.59 (Ph 3,5- C_2), 117.33 (Ph 1-C), 119.33 (3-C), 122.18 (4a-C), 129.25 (Ph 2,6- C_2), 143.61 (7-C), 148.21 (2-C), 150.70 (Ph 4-C), 151.69 (4-C), 152.58 (8a-C), 160.61 (5-C); MS m/z 252 (M) $^+$.

4.1.24. 7-Phenyl-1,6-naphthyridin-5-one 1-oxide (**13a**)

Urea. H_2O_2 complex (78 mg, 0.8 mmol) was added to **9a** (100 mg, 0.45 mmol) in DMF (15 mL). The mixture was cooled to 0°C. (F_3CCO) $_2\text{O}$ (189 mg, 0.9 mmol) was added dropwise. The mixture was stirred at 0°C for 12 h. The precipitate was collected and washed (water, CHCl_3). The solvent was evaporated from the combined filtrate and washings. Chromatography (petroleum ether / EtOAc 1:7 $\rightarrow$ AcOH / petroleum ether / EtOAc 1:3:21) gave **13a** (51 mg, 50%) as a white solid; mp 293-295°C; IR ν_{max} 3434, 1678, 1620, 1585, 1505, 1244 cm^{-1} ; ^1H NMR δ 7.31 (s, 8-H), 7.41 (1 H, dd, J = 8.0, 6.5 Hz, 3-H), 7.53 (3 H, m, Ph 3,4,5- H_3), 7.83 (2 H, d, J = 8.0 Hz, Ph 2,6- H_2), 7.99 (1 H, dd, J = 8.0, 1.0 Hz, 4-H), 8.62 (1 H, dd, J = 6.5, 1.0 Hz, 2-H); ^{13}C NMR δ 93.77 (8-C), 121.90 (4a-C), 123.19 (3-C), 123.31 (Ph 4-C), 127.15 (Ph 2,6- C_2), 128.95 (Ph 3,5- C_2), 130.29 (4-C), 137.31 (Ph 1-C), 140.80 (7-C), 162.11 (8a-C); ^{15}N NMR δ 252.76 (s, 1-N), 129.56 (s, 6-N).

4.1.25. 7-(4-Methylphenyl)-1,6-naphthyridin-5-one 1-oxide (**13b**)

Urea. H_2O_2 complex (60 mg, 0.6 mmol) was added to **9b** (75 mg, 0.3 mmol) in DMF (10 mL). The mixture was cooled to 0°C. (F_3CCO) $_2\text{O}$ (123 mg, 0.6 mmol) was added dropwise. The mixture was stirred at 0°C for 12 h. The precipitate was collected and washed (water, Me_2CO). The solvent was evaporated from the filtrates. Recrystallisation (EtOAc / petroleum ether) gave **13b** (20 mg, 29%) as a white solid; mp 258-260°C; IR ν_{max} 3450, 1654, 1581, 1284 cm^{-1} ; ^1H NMR δ 2.38 (3 H, s, Me), 6.90 (1 H, s, 8-H), 7.32 (2 H, d, J = 8.5 Hz, Ph 3,5- H_2), 7.47 (1 H, dd, J = 8.0, 4.5 Hz, 3-H), 7.73 (2 H, d, J = 8.5 Hz, Ph 2,6- H_2), 8.50 (1 H, dd, J = 7.5, 1.0 Hz, 4-H), 8.62 (1 H, dd, J = 4.5, 1.5 Hz, 2-H), 11.78 (1 H, s, 6-H); ^{13}C NMR δ 20.84 (Me), 103.99 (8-C), 121.49 (3-C), 126.86 (Ph 2,6- C_2), 129.42 (Ph 3,5- C_2), 135.03 (4-C), 154.96 (2-C); MS m/z 253.0996 ($\text{M} + \text{H}$) $^+$, ($\text{C}_{15}\text{H}_{13}\text{N}_2\text{O}_2$ requires 253.0972).

4.1.26. 2-Phenylpyrido[2,3-*d*]pyrimidin-4-one (**14a**)

Compound **38** (101.5 mg, 0.5 mmol), **45a** (60 mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs_2CO_3 (325 mg, 1.0 mmol) were stirred in DMF (5 mL) under Ar for 10 h, then at 80°C for 3 h, before being cooled and filtered. The evaporation residue, in MeOH, was filtered. The evaporation residue, in EtOAc / CH_2Cl_2 , was filtered. The filtrate was washed (aq. EDTA). The aq. layer was extracted with CH_2Cl_2 (6 $\times$) and with EtOAc (6 $\times$). Drying and evaporation gave **14a** (58 mg, 53%) as an off-white solid: mp 285-287 °C (lit.⁴⁸ mp 284-285°C); ^1H NMR (CDCl_3) δ 7.45 (1 H, dd, 7-H), 7.60 (5 H, m, Ph- H_5), 8.41 (1 H, dd, J = 7.5, 2.0 Hz, 8-H), 8.91 (1 H, dd, J = 4.5, 2.0 Hz, 6-H), 11.10 (1 H, br, NH); ^{13}C NMR (CDCl_3) δ 116.11 (8a-C), 121.48 (7C), 128.49 (Ph 3,5- C_2), 128.98 (3C), 129.10 (Ph 2,6- C_2), 132.53 (Ph 4-C), 134.06 (Ph 1-C), 140.16 (8-C), 155.49 (6-C), 159.26 (4a-C), 166.46 (1-C); MS m/z 242.0957 ($\text{M} + \text{H}_2\text{O} + \text{H}$) $^+$ ($\text{C}_{13}\text{H}_{12}\text{N}_3\text{O}_2$ requires 242.0923), 224.0835 ($\text{M} + \text{H}$) $^+$ ($\text{C}_{13}\text{H}_{10}\text{N}_3\text{O}$ requires 224.0818).

4.1.27. 2-(4-Methylphenyl)pyrido[2,3-*d*]pyrimidin-4-one (**14b**)

Compound **38** (101.5 mg, 0.5 mmol) was stirred with **45b** (67 mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs_2CO_3 (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 10 h under Ar. The mixture was filtered. The evaporation residue, in MeOH, was filtered. The evaporation residue, in sat. aq. EDTA (20 mL), was kept at 2-8 °C for 30 min and the solid was collected. The solid was washed (petroleum ether, water) and was dried to give **14b** (41 mg, 35%) as a white powder: mp 249-251°C, ^1H NMR δ 2.47 (3 H, s, Me), 7.28 (1 H, dd, J = 7.4, 5.1 Hz, 6-H), 7.48 (2 H, d, J = 8.1 Hz, Ph 3,5- H_2), 7.94 (2 H, d, J = 8.1 Hz, Ph 2,6- H_2), 8.44 (1 H, d, J = 7.5 Hz, 5-H), 8.48 (1 H, d, J = 4.7 Hz, 7-H), 11.09 (1 H, br, NH); ^{13}C NMR δ 20.99 (Me), 119.07 (4a-C), 119.84 (6-C), 127.31 (Ph 3,5- C_2), 129.53 (Ph 1-C), 129.61 (Ph 2,6- C_2), 140.15 (5-C), 142.84 (Ph 4-C), 148.29 (7-C), 155.60 (8a-C), 159.67 (2-C), 166.78 (4-C); MS m/z 236.0836 ($\text{M} - \text{H}$) $^-$ ($\text{C}_{14}\text{H}_{10}\text{N}_3\text{O}$ requires 236.0824).

4.1.28. 2-(4-Trifluoromethylphenyl)pyrido[2,3-*d*]pyrimidin-4-one (**14d**)

Compound **38** (101.5 mg, 0.5 mmol) was stirred with **45d** (94 mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs_2CO_3 (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 10 h under Ar. The mixture was filtered. The evaporation residue, in MeOH, was filtered. The evaporation residue was treated with sat. aq. EDTA (20 mL) at 2-8 °C for 30 min. The solid was collected, washed (petroleum ether, water) and dried to give **14d** (64 mg, 45%) as a white powder: mp 254-256°C; ^1H NMR δ 7.29 (1 H, dd, J = 6.8, 4.0 Hz, 6-H), 8.04 (2 H, m, Ph 2,6- H_2), 8.22 (2 H, m, Ph 3,5- H_2), 8.46 (1 H, d, J = 7.0 Hz, 5-H), 8.54 (1 H, d, J =

4.0 Hz, 7-H), 11.01 (1 H, br, NH); ^{13}C NMR δ 119.0 (6-C), 126.10 (Ph 2,6-C₂), 128.22 (q J = 2.7 Hz, Ph 3,5-C₂), 140.10 (5-C), 149.5 (7-C); ^{19}F NMR δ -61.35 (CF₃); MS 292.0699 (M + H)⁺ (C₁₄H₉F₃N₃O requires 292.0692).

4.1.29. 2-(4-Chlorophenyl)pyrido[2,3-*d*]pyrimidin-4-one (14e)

Compound **38** (101.5 mg, 0.5 mmol) was stirred with **45e** (77 mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 10 h under Ar. The mixture was filtered. The evaporation residue, in MeOH, was filtered. The evaporation residue was treated with sat. aq. EDTA (20 mL) at 2-8 °C for 30 min. The solid was collected and recrystallised (EtOAc / CH₂Cl₂) to give **14e** (10 mg, 8%) as a pale grey powder: mp 266-268°C (lit.⁴⁹ mp 300.5°C); ^1H NMR δ 7.25 (1 H, m, 6-H), 7.73 (2 H, d, J = 8.9 Hz, Ph 2,6-H₂), 8.06 (2 H, d, J = 8.9 Hz, Ph 3,5-H₂), 8.42 (1 H, m, 5-H), 8.45 (1 H, m, 7-H), 11.10 (1 H, br NH); ^{13}C NMR δ 119.30 (4a-C), 119.75 (6-C), 129.27 (Ph 3,5-C₂), 129.50 (Ph 2,6-C₂), 132.0 (Ph 1-C), 137.0 (Ph 4-C), 140.25 (5-C), 149.34 (7-C), 151.0 (8a-C), 156.99 (2-C), 160.15 (1-C); MS m/z 537.0621 (2 M + Na)⁺ (C₂₆H₁₆³⁵Cl₂N₆NaO₂ requires 537.0598), 282.0225 (M + Na)⁺ (C₁₃H₈³⁷ClN₃NaO requires 282.0224), 280.0257 (M + Na)⁺ (C₁₃H₈³⁵ClN₃NaO requires 280.0254).

4.1.30. 2-Phenylpyrido[3,4-*d*]pyrimidin-4-one (15a)

Compound **31** (101.5 mg, 0.50 mmol) was stirred with **45a** (60 mg, 0.50 mmol), CuI (19 mg, 0.10 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 12 h under Ar. The evaporation residue, in MeOH, was filtered. The evaporation residue, in sat. aq. EDTA (20 mL), was sonicated for 5 min. The solution was kept at 2-8°C for 1 h. The solid was collected. The filtrate was extracted with EtOAc (4 ×). The combined extracts were dried and the solvent was evaporated. Washing (water, petroleum ether) and drying gave **15a** (14 mg, 13%) as a white powder: mp 228-230°C (lit.⁵⁰ mp 266-267°C); ^1H NMR δ 7.62 (3 H, m, Ph 3,4,5-H₃), 8.02 (1 H, d, J = 5.0 Hz, 5-H), 8.26 (2 H, d, J = 6.9 Hz, Ph 2,6-H₂), 8.68 (1 H, d, J = 5.0 Hz, 6-H), 9.16 (1 H, s, 8-H), 10.40 (1 H, br, NH); ^{13}C NMR δ 118.09 (5-C), 127.42 (Ph 1-C), 127.93 (Ph 2,6-C₂), 128.97 (Ph 3,5-C₂), 129.04 (4a-C), 131.56 (8a-C), 132.99 (Ph 4-C), 145.44 (6-C), 150.70 (8-C), 155.07 (2-C), 162.13 (4-C); MS m/z 469.1398 (2 M + Na)⁺ (C₂₆H₁₈N₆NaO₂ requires 469.1384), 246.0638 (M + Na)⁺ (C₁₃H₉N₃NaO requires 246.0641).

4.1.31. 2-(4-Methylphenyl)pyrido[3,4-*d*]pyrimidin-4-one (15b)

Compound **31** (101.5 mg, 0.50 mmol) was stirred with **45b** (67 mg, 0.50 mmol), CuI (19 mg, 0.10 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 12 h under Ar. The evaporation residue, in MeOH, was filtered. The evaporation residue, in sat. aq. EDTA (20 mL), was extracted thrice with CH₂Cl₂. Drying and evaporation gave **15b** (10 mg, 9%) as a white powder: mp 214-216°C; ^1H NMR δ 2.44 (3 H, s, Me), 7.36 (2 H, d, J = 8.1 Hz, Ph 3,5-H₂), 7.91 (1 H, d, J = 5.2 Hz, 5-H), 8.24 (2 H, d, J = 8.2 Hz, Ph 2,6-H₂), 8.52 (1 H, d, J = 5.2 Hz, 6-H), 9.03 (1 H, s, 7-H), 10.20 (1 H, br, NH); ^{13}C NMR δ 20.97 (Me), 118.16 (5-C), 126.00 (4a-C), 127.47 (Ph 1-C), 127.47 (Ph 2,6-C₂), 128.85 (Ph 3,5-C₂), 129.45 (Ph 4-C), 144.00 (6-C), 149.00 (8a-C), 150.40 (8-C), 168.90 (2-C); MS m/z 236.0836 (M - H)⁻ (C₁₄H₁₀N₃O requires 236.0824).

4.1.32. 2-(4-Trifluoromethylphenyl)pyrido[3,4-*d*]pyrimidin-4-one (15d)

Compound **31** (101.5 mg, 0.50 mmol) was stirred with **45d** (94 mg, 0.5 mmol), CuI (19.2 mmol, 0.1 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 10 h under Ar. The mixture was filtered. The evaporation residue was suspended in MeOH and the suspension was filtered. The evaporation residue, sat. aq. EDTA (20 mL) was kept at 2-8°C

for 1 h and the solid was collected. The filtrate was extracted with EtOAc (6 ×). The combined extracts were dried and the solvent was evaporated. Washing (petroleum ether, water) and drying gave **15d** (34 mg, 24%) as an off-white powder: mp > 300°C (decomp.); ^1H NMR δ 7.87 (2 H, d, J = 8.3 Hz, Ph 2,6-H₂), 8.12 (1 H, m, 5-H), 8.43 (2 H, d, J = 8.2 Hz, Ph 3,5-H₂), 8.71 (1 H, br, 6-H), 9.23 (1 H, br, 8-H), 13.10 (1 H, br, NH); ^{13}C NMR δ 125.24 (q, J = 289.3 Hz, CF₃), 125.56 (q, J = 2.3 Hz, Ph 3,5-C₂), 128.91 (Ph 2,6-C₂), 131.5 (4a-C), 136.27 (q, J = 31.7 Hz, Ph 4-C), 138.0 (Ph 1-C), 147.0 (5-C), 149.0 (8-C), 154.0 (2-C), 155.5 (6-C), 158.0 (8a-C), 161.32 (4-C); MS m/z 314 (M + Na)⁺, 292.0705 (M + H)⁺ (C₁₄H₉F₃N₃O requires 292.0692).

4.1.33. 2-Phenylpyrido[4,3-*d*]pyrimidin-4-one (16a)

Compound **37** (101.5 mg, 0.5 mmol) was stirred with **45a** (60 mg, 0.5 mmol), CuI (19.2 mg, 0.1 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 50°C for 10 h under Ar. The mixture was filtered. The evaporation residue was suspended in MeOH and filtered. The evaporation residue, in sat. aq. EDTA (20 mL), was sonicated for 5 min. This mixture was extracted with EtOAc (6 ×). Drying and evaporation gave **16a** (50 mg, 44%) as an off-white powder: mp 273-275°C (lit.⁵¹ 284-286°C); ^1H NMR δ 7.61 (1 H, m, 8-H), 7.63 (3 H, m, Ph 3,4,5-H₃), 8.28 (2 H, d, J = 7.2 Hz, Ph 2,6-H₂), 8.83 (1 H, br, 7-H), 9.33 (1 H, br, 5-H), 12.80 (1 H, br, NH); ^{13}C NMR δ 117.5 (4a-C), 120.0 (8-C), 124.0 (Ph 1-C), 128.26 (Ph 3,5-C₂), 128.64 (Ph 2,6-C₂), 132.0 (Ph 4-C), 135.0 (3-C), 149.0 (5-C), 152.0 (7-C), 156.0 (8a-C), 162.0 (4-C); MS m/z 469.1396 (2 M + Na)⁺ (C₂₆H₁₈N₆NaO₂ requires 469.1389), 246.0644 (M + Na)⁺ (C₁₃H₉N₃NaO requires 246.0643), 224.0828 (M + H)⁺ (C₁₃H₁₀N₃O requires 224.0818).

4.1.34. 2-(4-Methylphenyl)pyrido[4,3-*d*]pyrimidin-4-one (16b)

Compound **37** (101.5 mg, 0.5 mmol) was stirred with **45b** (67 mg, 0.5 mmol), CuI (19.2 mmol, 0.1 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 12 h under Ar. The mixture was filtered. The evaporation residue was suspended in MeOH and filtered. The evaporation residue, in sat. aq. EDTA (20 mL), was extracted with EtOAc (6 ×). Drying and evaporation gave **16b** (46 mg, 42%) as an off-white powder: mp 276-278°C (lit.⁵¹ 296-299°C); ^1H NMR δ 2.45 (3 H, s, Me), 7.29 (2 H, d, J = 8.0 Hz, Ph 3,5-H₂), 7.64 (1 H, d, J = 5.4 Hz, 5-H), 8.18 (2 H, d, J = 8.2 Hz, Ph 2,6-H₂), 8.85 (1 H, br, 6-H), 9.33 (1 H, br, 8-H); ^{13}C NMR δ 21.0 (Me), 120.12 (8a-C), 120.39 (5-C), 128.17 (Ph 2,6-C₂), 129.21 (Ph 3,5-C₂), 129.82 (Ph 1-C), 131.48 (Ph 4-C), 142.27 (3-C), 149.45 (8-C), 157.37 (4a-C), 162.37 (1-C); MS m/z 238.0984 (M + H)⁺ (C₁₄H₁₂N₃O requires 238.0980).

4.1.35. 2-(4-Trifluoromethylphenyl)pyrido[4,3-*d*]pyrimidin-4-one (16d)

Compound **37** (101.5 mg, 0.5 mmol) was stirred with **45d** (94 mg, 0.5 mmol), CuI (19.2 mmol, 0.1 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 3 h, then at 20°C for 10 h under Ar. The mixture was filtered. The evaporation residue was suspended in MeOH. The suspension was filtered. The evaporation residue, in sat. aq. EDTA, was kept at 2-8 °C for 1 h and the solid was collected. The filtrate was extracted with EtOAc (6 ×). The extracts were dried and the solvent was evaporated. Washing (petroleum ether, water) and drying gave **16d** (70 mg, 50%) as an off-white powder: mp 267-268°C; ^1H NMR δ 7.71 (1 H, d, J = 4.4 Hz, 8-H), 8.00 (2 H, d, J = 8.3 Hz, Ph 2,6-H₂), 8.44 (2 H, d, J = 8.2 Hz, Ph 3,5-H₂), 9.08 (1 H, br, 7-H), 9.38 (1 H, br, 5-H), 13.10 (1 H, br, NH); ^{13}C NMR δ 122.04 (8a-C), 125.21 (8-C), 125.24 (Ph 2,6-C₂), 125.51 (q, J = 3.5 Hz, Ph 3,5-C₂), 129.17 (6-C), 131.76 (q, J = 340.6 Hz, CF₃), 134.0 (q, J = 27.5 Hz, Ph 4-C), 138.0 (Ph 1-C), 149.53 (5-C), 153.49 (4a-C), 156.32 (3-C), 162.0 (1-C); ^{19}F NMR δ -61.34 (s, CF₃); MS m/z 605 (2 M +

Na)⁺, 314.0496 (M + Na)⁺ (C₁₄H₈F₃N₃NaO requires 314.0517), 292.0702 (M + H)⁺ (C₁₄H₉F₃N₃O requires 292.0698).

4.1.36. 2-(4-Chlorophenyl)pyrido[4,3-*d*]pyrimidin-4-one (16e)

Compound **37** (101.5 mg, 0.5 mmol) was stirred with **45e** (77.3 mg, 0.5 mmol), CuI (19.2 mmol, 0.1 mmol) and Cs₂CO₃ (325 mg, 1.0 mmol) in DMF (5 mL) at 80°C for 12 h under Ar. The mixture was filtered. The evaporation residue, in MeOH, was filtered. The evaporation residue, in sat. aq. EDTA (20 mL), was extracted with EtOAc (6 ×). The combined extracts were dried. The evaporation residue was washed (petroleum ether, water) and dried to give **16e** (17 mg, 13%) as a white powder: mp >300° (decomp.); ¹H NMR δ 7.66 (1 H, d, *J* = 5.6 Hz, 5-H), 7.69 (2 H, d, *J* = 8.6 Hz, Ph 2,6-H₂), 8.29 (2 H, d, *J* = 8.6 Hz, Ph 3,5-H₂), 8.86 (1 H, d, *J* = 5.5 Hz, 6-H), 9.34 (1 H, br, 8-H), 13.05 (1 H, br, NH); ¹³C NMR δ 120.0 (5-C), 126.50 (8a-C), 128.78 (Ph 3,5-C₂), 130.09 (Ph 2,6-C₂), 131.02 (Ph 4-C), 137.15 (Ph 1-C), 146.0 (4-C), 153.52 (8-C), 155.99 (3-C), 162.0 (1-C); MS *m/z* 282.0269 (M + Na)⁺ (requires 282.0224), 280.0260 (M + Na)⁺ (C₁₃H₈³⁵ClN₃NaO requires 280.0254).

4.1.37. 1-Methyl-7-phenyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-one (17a)

BH₃.pyridine complex (60 μL) was added to **12a** (80 mg, 0.22 mmol) in HCO₂H (5 mL) at 0°C and the mixture was stirred for 5 d at 20°C. Daily, additional BH₃.pyridine (10 μL) was added. Evaporation, trituration (MeOH; 10 mL) and recrystallisation (PrⁱOH) gave **17a** (21 mg, 20%) as a pale grey solid: mp 315–317°C; IR ν_{max} 1655, 1620 cm⁻¹; ¹H NMR (CDCl₃) δ 1.89 (2 H, m, 3-H₂), 2.51 (2 H, m, 4-H₂), 3.11 (3 H, s, Me), 3.36 (2 H, m, 2-H₂), 6.30 (1 H, s, 8-H), 7.43 (3 H, m, Ph 3,4,5-H₃), 7.68 (2 H, m, Ph 2,6-H₂); ¹³C NMR (CDCl₃) δ 19.59 (4-C), 20.12 (Me), 50.78 (2-C), 96.80 (8-C), 100.22 (4a-C), 126.58 (Ph 2,6-C₂), 129.25 (Ph 3,5-C₂), 130.47 (4-C), 132.79 (Ph 1-C), 144.28 (7-C), 155.00 (8a-C), 158.96 (5-C); MS *m/z* 503 (2 M + Na)⁺, 263.1177 (M + Na) (C₁₅H₁₆N₂NaO requires 263.1160).

4.1.38. 7-(4-Methoxyphenyl)-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-one (17c)

BH₃.Py complex (0.10 mL) was added dropwise to **12c** (50 mg, 0.13 mmol) in HCO₂H (5 mL) at 0°C and the mixture was stirred at 20°C for 5 d. Daily, additional BH₃.Py (0.01 mL) was added. The evaporation residue, in AcOH (2 mL), was diluted with water (10 mL). The mixture was extracted (EtOAc, 3×). Evaporation and recrystallisation (water) gave **17c** (1.0 mg, 3%) as a white powder: mp 221–223°C; ¹H NMR (CDCl₃) δ 1.93 (2 H, qn, *J* = 6.2 Hz, 3-H₂), 2.61 (2 H, t, *J* = 6.4 Hz, 4-H₂), 3.02 (3 H, s, NMe), 3.28 (2 H, t, *J* = 5.4 Hz, 2-H₂), 3.85 (3 H, s, OMe), 5.98 (1 H, s, 8-H), 6.96 (2 H, d, *J* = 8.9 Hz, Ph 3,5-H₂), 7.47 (2 H, d, *J* = 8.9 Hz, Ph 2,6-H₂); ¹³C NMR (CDCl₃) δ 20.60 (4-C), 20.83 (3-C), 38.81 (NMe), 50.79 (2-C), 55.44 (OMe), 94.01 (8-C), 100.49 (4a-C), 114.62 (Ph 3,5-C₂), 126.95 (Ph 1-C), 127.18 (Ph 2,6-C₂), 142.51 (Ph 4-C), 153.33 (8a-C), 160.67 (7-C), 162.28 (5-C); MS *m/z* 563 (2 M + Na)⁺, 541 (2 M + H)⁺, 293.1259 (M + Na)⁺ (C₁₆H₁₈N₂NaO₂ requires 293.1266), 271.1452 (M + H)⁺ (C₁₆H₁₉N₂O₂ requires 271.1447).

4.1.39. 1-Methyl-7-(4-trifluoromethylphenyl)-1,2,3,4-tetrahydro-1,6-naphthyridin-5-one (17d)

BH₃.Py complex (0.10 mL) was added dropwise to **12d** (30 mg, 0.07 mmol) in HCOOH (5 mL) at 0°C. The mixture was stirred for 10 d at 20°C. Each day, additional BH₃.Py (0.01 mL) was added. The evaporation residue, in water (5 mL), was sonicated. The precipitate was collected and recrystallised (water) to give **17d** (5.0 mg, 24%) as a white powder: mp 287–288°C; ¹H NMR (CDCl₃) δ 1.94 (2 H, qn, *J* = 5.5 Hz, 3-H₂), 2.63 (2 H, t, *J* = 6.0 Hz, 4-H₂), 3.31 (2 H, t, *J* = 5.5 Hz, 2-H₂), 6.09 (1 H, s, 8-H), 7.67 (2 H, d, *J* = 8.5 Hz, Ph 2,6-H₂), 7.72 (2 H, d, *J* = 8.5 Hz,

Ph 3,5-H₂); ¹³C NMR (CDCl₃) δ 20.61 (4-C), 20.94 (3-C), 50.01 (2-C), 96.10 (8-C), 101.76 (4a-C), 125.10 (q, *J* = 275 Hz, CF₃), 126.38 (m, Ph 2,3,5,6-C₄), 131.95 (q, *J* = 37.5 Hz, Ph 4-C), 140.02 (Ph 1-C), 141.80 (7-C), 149.10 (5-C), 157.22 (8a-C); ¹⁹F NMR (CDCl₃) δ -62.79 (CF₃); MS *m/z* 639.2179 (2 M + Na)⁺ (C₃₂H₃₀F₆N₄NaO₂ requires 639.2171), 617.2372 (2 M + H)⁺ (C₃₂H₃₁F₆N₄O₂ requires 617.2351), 331.1061 (M + Na)⁺ (C₁₆H₁₅F₃N₂NaO requires 331.1034), 309.1239 (M + H)⁺ (C₁₆H₁₆F₃N₂O requires 309.1215).

4.1.40. 7-(4-Chlorophenyl)-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-one (17e)

Compound **12e** was treated with BH₃.Py complex, as for the synthesis of **17d**, to give **17e** (44%) as a white powder: mp 195–197°C; ¹H NMR (CDCl₃) δ 1.95 (2 H, qn, *J* = 6.4 Hz, 3-H₂), 2.60 (2 H, t, *J* = 6.4 Hz, 4-H₂), 3.04 (3 H, s, NMe), 3.30 (2 H, t, *J* = 5.6 Hz, 2-H₂), 6.06 (1 H, s, 8-H), 7.43 (2 H, d, *J* = 8.6 Hz, Ph 3,5-H₂), 7.54 (2 H, d, *J* = 8.7 Hz, Ph 2,6-H₂); ¹³C NMR (CDCl₃) δ 20.62 (4-C), 20.83 (3-C), 38.76 (NMe), 50.43 (2-C), 95.28 (8-C), 101.97 (4a-C), 127.54 (Ph 2,6-C₂), 129.33 (Ph 3,5-C₂), 134.29 (Ph 1-C), 137.70 (Ph 4-C), 142.30 (7-C), 153.97 (8a-C), 157.50 (5-C); MS *m/z* 549.1819 (2 M + H)⁺ (C₃₀H₃₁³⁵ClN₂O requires 549.1824), 275.0941 (M + H)⁺ (C₁₅H₁₆³⁵ClN₂O requires 275.0946).

4.1.41. 7-(4-Bromophenyl)-1-methyl-1,2,3,4-tetrahydro-1,6-naphthyridin-5-one (17f)

Compound **12f** was treated with BH₃.Py complex, as for the synthesis of **17d**, to give **17f** (47%) as a white powder: mp 205–207°C; ¹H NMR (CDCl₃) δ 1.95 (2 H, qn, *J* = 6.4 Hz, 3-H₂), 2.61 (2 H, t, *J* = 6.3 Hz, 4-H₂), 3.29 (3 H, s, Me), 3.29 (2 H, t, *J* = 5.5 Hz, 2-H₂), 6.02 (1 H, s, 8-H), 7.42 (2 H, d, *J* = 8.7 Hz, Ph 2,6-H₂), 7.59 (2 H, d, *J* = 8.7 Hz, Ph 3,5-H₂); ¹³C NMR (CDCl₃) δ 20.75 (4-C), 21.63 (3-C), 38.70 (NMe), 50.76 (2-C), 94.44 (8-C), 101.46 (4a-C), 123.93 (Ph 4-C), 127.41 (Ph 2,6-C₂), 132.27 (Ph 3,5-C₂), 133.39 (Ph 1-C), 141.80 (7-C), 153.16 (8a-C), 162.35 (5-C); MS *m/z* 663 / 661 / 659 (2 M + Na)⁺, 641 / 639 / 637 (2 M + H)⁺, 343.0249 (M + Na)⁺ (C₁₅H₁₅⁸¹BrN₂NaO requires 343.0246), 341.0264 (M + Na)⁺ (C₁₅H₁₅⁷⁹BrN₂NaO requires 341.0266), 321.0426 (M + H)⁺ (C₁₅H₁₆⁸¹BrN₂O requires 321.0426), 319.0448 (M + H)⁺ (C₁₅H₁₆⁷⁹BrN₂O requires 319.0446).

4.1.42. 4-Oxo-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-10-ium formate (18a)

Compound **47a** (50 mg, 0.16 mmol) was stirred with Pd/C (10%, 50 mg) in dry MeOH (10 mL) and HCO₂H (1.0 mL) for 10 h under Ar. Filtration (Celite[®]) and evaporation gave **18a** (32 mg, 89%) as an off-white powder: mp 244–245°C (decomp.) (lit.²² 214–216°C for free base); ¹H NMR δ 2.46 (2 H, m, 8-H₂), 3.20 (2 H, m, 7-H₂), 3.79 (2 H, s, 5-H₂), 7.59 (3 H, m, Ph 3,4,5-H₃), 8.14 (2 H, d, *J* = 7.2 Hz, Ph 2,6-H₂), 9.25 (2 H, br, 3-NH, 7-NH); ¹³C NMR δ 29.50 (8-C), 40.12 (5-C), 41.02 (7-C), 127.56 (Ph 3,5-C₂), 128.58 (Ph 2,6-C₂), 131.37 (Ph 4-C), 132.55 (Ph 1-C), 154.78 (4a-C), 158.03 (8a-C), 161.93 (2-C), 164.65 (4-C); MS *m/z* 477.2029 (2 M + Na)⁺ (C₂₆H₂₆N₆NaO₂ requires 477.2015), 250.0947 (M + Na)⁺ (C₁₃H₁₃N₃NaO requires 250.0956), 228.1169 (M + H)⁺ (C₁₃H₁₄N₃O requires 228.1137).

4.1.43. 2-(4-Methylphenyl)-4-oxo-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-10-ium formate (18b)

Compound **47b** was treated with Pd/C and HCO₂H in MeOH, as for the synthesis of **18a**, to give **18b** (86%) as an off-white powder: mp 279–280°C; ¹H NMR δ 2.42 (3 H, s, Me), 2.45 (2 H, m, 8-H₂), 2.73 (2 H, m, 7-H₂), 3.33 (2 H, s, 5-H₂), 7.36 (2 H, d, *J* = 7.9 Hz, Ph 3,5-H₂), 8.03 (2 H, d, *J* = 8.0 Hz, Ph 2,6-H₂), 8.31 (2 H, br, 3-NH, 7-NH); ¹³C NMR δ 20.94 (Me), 31.04 (7-C), 45.09 (8-C), 46.03 (5-C), 116.91 (4a-C), 127.45 (Ph 2,6-C₂), 129.16 (Ph 3,5-C₂), 129.50 (Ph 1-C), 141.41 (Ph 4-C), 154.08 (2-C),

158.07 (8a-C), 161.47 (4-C); MS m/z 242.1294 (M + H)⁺ (C₁₄H₁₆N₃O requires 242.1288).

4.1.44. 4-Oxo-2-(4-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidinium formate (**18d**)

Compound **47d** (was treated with Pd/C and HCO₂H in MeOH, as for the synthesis of **18a**, to give **18d** (68%) as an off-white powder: mp 280-281°C (decomp.); ¹H NMR δ 2.32 (2 H, m, 8-H₂), 2.55 (2 H, m, 7-H₂), 3.13 (2 H, s, 5-H₂), 7.66 (2 H, d, J = 8.5 Hz, Ph 3,5-H₂), 8.43 (2 H, d, J = 8 Hz, Ph 2,6-H₂); ¹³C NMR δ 31.52 (7-C), 46.07 (8-C), 53.41 (5-C), 114.42 (4a-C), 123.57 (q, J = 270.1 Hz, CF₃), 124.40 (q, J = 3.6 Hz, Ph 3,5-C₂), 127.77 (Ph 2,6-C₂), 128.41 (q, J = 31.1 Hz, Ph 4-C), 144.78 (Ph 1-C), 155.98 (8a-C), 156.99 (4-C), 159.29 (2-C); ¹⁹F NMR δ -60.69 (s, CF₃); MS m/z 296.1016 (M + H)⁺ (C₁₄H₁₃F₃N₃O requires 296.1005).

4.1.45. 2-(4-Phenylethynylphenyl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-one hydrochloride (**18j**)

Compound **47j** (170 mg, 0.41 mmol) was stirred for 10 h with Pd/C (10%, 200 mg) in dry MeOH (10 mL) and HCOOH (1.0 mL). The mixture was filtered through Celite®. The evaporation residue was recrystallised (EtOH). The formate salt was treated with HCl in dioxane (4.0 M, 3.0 mL) and Et₂O (5 mL). The precipitate was collected and washed (petroleum ether) to give **18j** (44 mg, 34%) as a white crystalline powder: mp >260°C (decomp.); ¹H NMR δ 2.92-2.95 (4 H, m, 7,8-H₄), 4.02-4.04 (2 H, m, 5-H₂), 7.24 (1 H, m, Ph' 4-H), 7.28 (2 H, d, J = 7.3 Hz, Ph 3,5-H₂), 7.30-7.35 (4 H, m, Ph' 2,3,5,6-H₄), 7.41 (2 H, d, J = 8.1 Hz, Ph 2,6-H₂), 8.26 (2 H, br, +NH₂); ¹³C NMR δ 36.52 (8-C), 36.86 (7-C), 41.88 (5-C), 66.32 (ethynyl 1-C), 92.21 (ethynyl 2-C), 128.21 (Ph' 3,5-C₂), 128.33 (Ph 3,5-C₂), 128.37 (Ph 4-C), 128.53 (Ph' 2,6-C₂), 128.68 (Ph' 1-C), 128.77 (Ph 1-C), 128.86 (Ph 2,6-C₂), 131.49 (4a-C), 141.29 (8a-C), 141.82 (2-C), 167.31 (4-C); MS m/z 350.1263 (M + Na)⁺ (C₂₁H₁₇N₃NaO requires 350.1269).

4.1.46. 4-Oxo-2-(pyridin-4-yl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidinium formate (**18l**)

Compound **47l** was treated with Pd/C and HCO₂H in MeOH, as for the synthesis of **18a**, to give **18l** (80%) as an off-white powder: mp 242-244°C (lit.⁵² 244-246°C); ¹H NMR δ 3.02 (2 H, m, 8-H₂), 3.27 (2 H, m, 7-H₂), 3.44 (2 H, s, 5-H₂), 7.16 (2 H, d, J = 8.2 Hz, Py 2,6-H₂), 7.53 (2 H, d, J = 8.1 Hz, Py 3,5-H₂); ¹³C NMR δ 31.14 (7-C), 45.32 (8-C), 50.61 (5-C), 116.89 (4a-C), 117.21 (Py 1-C), 125.53 (Py 2,6-C₂), 128.10 (Py 3,5-C₂), 156.85 (8a-C), 160.38 (4-C), 161.20 (2-C).

4.1.47. 3-Cyano-2-phenylethynylpyridine (**25a**)

Compound **24** (150 mg, 0.80 mmol) in THF (5 mL) was stirred with CuI (15.2 mg, 80 μmol) and (Ph₃P)₂PdCl₂ (28 mg, 40 μmol) in Pr₂NH (5 mL) under Ar at 45°C for 30 min. Phenylethyne **21a** (163 mg, 1.6 mmol) was added. The mixture was stirred at 40°C for 5 d. Evaporation and chromatography (petroleum ether / EtOAc 3:1) gave **25a** (80 mg, 50%) as a pale buff powder: mp 83-85°C (lit.⁵³ mp 85-87°C); ¹H NMR (CDCl₃) δ 7.33 (1 H, dd, J = 8.0, 4.8 Hz, 5-H), 7.40 (3 H, m, Ph 3,4,5-H₃), 7.68 (d, J = 7.6 Hz, Ph 2,6-H₂), 7.95 (1 H, dd, J = 8.0, 2.0 Hz, 4-H), 8.77 (1 H, dd, J = 4.8, 1.6 Hz, 6-H); ¹³C NMR (CDCl₃) δ 85.62 (ethyne 2-C), 96.20 (ethyne 1-C), 112.82 (3-C), 115.91 (C≡N), 120.98 (5-C), 121.87 (Ph 1-C), 128.47 (Ph 3,5-C₂), 129.99 (Ph 4-C), 132.47 (Ph 2,6-C₂), 139.76 (4-C), 146.04 (2-C), 152.77 (6-C); MS m/z 227.0575 (M + Na)⁺ (C₁₄H₈N₂Na requires 227.0586), 205.0755 (M + H)⁺ (C₁₄H₈N₂ requires 205.0766).

4.1.48. 3-Cyano-2-(4-methylphenylethynyl)pyridine (**25b**)

1-Ethynyl-4-methylbenzene **21b** was treated with **24**, CuI, Na ascorbate and (Ph₃P)₂PdCl₂ in Pr₂NH and THF, as for the synthesis of **25a**, except that the chromatographic eluent was petrol-

eum ether / EtOAc (5:1 → 3:1), to give **25b** (80%) as a pale buff powder: mp 175-178°C; ¹H NMR (CDCl₃) δ 2.40 (3 H, s, Me), 7.21 (2 H, J = 8.2 Hz, Ph 3,5-H₂), 7.33 (1 H, dd, J = 8.0, 4.9 Hz, 5-H), 7.59 (2 H, d, J = 8.1 Hz, Ph 2,6-H₂), 7.97 (1 H, dd, J = 8.0, 1.8 Hz, 4-H), 8.78 (1 H, dd, J = 4.9, 1.7 Hz, 6-H); ¹³C NMR (CDCl₃) δ 21.70 (Me), 112.66 (2-C), 121.73 (5-C), 129.32 (Ph 3,5-C₂), 132.50 (Ph 2,6-C₂), 139.84 (4-C), 140.61 (Ph 4-C), 152.8 (6-C); MS m/z 241.0709 (M + Na)⁺ (C₁₅H₉N₂Na requires 241.0742), 219.0905 (M + H)⁺ (C₁₅H₁₁N₂ requires 219.0922).

4.1.48. 3-Cyano-2-(4-methoxyphenylethynyl)pyridine (**25c**)

Compound **21c** was treated with **24**, CuI, Na ascorbate and (Ph₃P)₂PdCl₂ in Pr₂NH and THF, as for the synthesis of **25b**, to give **25c** (81%) as a pale buff powder: mp 118-120°C; ¹H NMR (CDCl₃) δ 3.83 (3 H, s, Me), 6.90 (2 H, d, J = 8.9 Hz, Ph 3,5-H₂), 7.30 (1 H, dd, J = 8.0, 4.9 Hz, 5-H), 7.62 (2 H, d, J = 8.9 Hz, Ph 2,6-H₂), 7.93 (1 H, dd, J = 8.2, 2.1 Hz, 4-H), 8.75 (1 H, dd, J = 4.9, 1.7 Hz, 6-H); ¹³C NMR δ 55.32 (Me), 85.01 (ethyne 2-C), 96.94 (ethyne 1-C), 112.94 (5-C), 114.22 (Ph 3,5-C₂), 116.09 (C≡N), 121.45 (3-C), 134.23 (Ph 2,6-C₂), 139.74 (4-C), 146.36 (6-C), 152.74 (2-C), 161.05 (Ph 4-C); MS m/z 257.0695 (M + Na)⁺ (C₁₅H₁₀N₂NaO requires 257.0690).

4.1.50. 3-Cyano-2-(4-trifluoromethylphenylethynyl)pyridine (**25d**)

Compound **21d** was treated with **24**, CuI, Na ascorbate and (Ph₃P)₂PdCl₂ in Pr₂NH and THF, as for the synthesis of **25b**, to give **25d** (55%) as a pale buff powder: mp 129-132°C; ¹H NMR (CDCl₃) δ 7.40 (1 H, dd, J = 7.9, 4.9 Hz, 5-H), 7.66 (2 H, d, J = 8.0 Hz, Ph 3,5-H₂), 7.79 (2 H, d, J = 8.0 Hz, Ph 2,6-H₂), 8.00 (1 H, dd, J = 8.0, 1.8 Hz, 4-H), 8.81 (1 H, dd, J = 4.9, 1.8 Hz, 6-H); ¹³C NMR (CDCl₃) δ 87.25 (ethyne 2-C), 94.03 (ethyne 1-C), 113.22 (3-C), 115.78 (C≡N), 122.50 (5-C), 123 (CF₃), 124.73 (Ph 1-C), 125.49 (q, J = 3.6 Hz, Ph 3,5-C₂), 131.8 (q, J = ca. 30 Hz, Ph 4-C), 132.75 (Ph 2,6-C₂), 139.87 (4-C), 145.48 (2-C), 152.95 (6-C); ¹⁹F NMR (CDCl₃) δ -63.03 (s, CF₃); MS m/z 295.0428 (M + Na)⁺ (C₁₅H₇F₃N₂Na requires 295.0459), 273.0622 (M + H)⁺ (C₁₅H₈N₂F₃ requires 273.0640).

4.1.51. 2-(4-Chlorophenylethynyl)-3-cyanopyridine (**25e**)

Compound **21e** was treated with **24**, CuI, Na ascorbate and (Ph₃P)₂PdCl₂ in Pr₂NH and THF, as for the synthesis of **25b**, to give **25e** (42%) as an amber powder: mp 84-86°C; ¹H NMR (CDCl₃) δ 7.36 (1 H, dd, J = 7.9, 4.8 Hz, 5-H), 7.37 (2 H, d, J = 8.7 Hz, Ph 3,5-H₂), 7.61 (2 H, d, J = 8.7 Hz, Ph 2,6-H₂), 7.98 (1 H, dd, J = 7.9, 1.7 Hz, 4-H), 8.79 (1 H, dd, J = 5.0, 1.7 Hz, 6-H); ¹³C NMR (CDCl₃) δ 86.38 (ethyne 2-C), 94.80 (ethyne 1-C), 112.87 (3-C), 115.82 (C≡N), 119.43 (Ph 1-C), 122.31 (5-C), 128.92 (Ph 3,5-C₂), 133.63 (Ph 2,6-C₂), 136.30 (Ph 4-C), 139.77 (4-C), 145.75 (2-C), 152.85 (6-C); MS m/z 239.0353 (M + H)⁺ (C₁₄H₈³⁵ClN₂H requires 239.0376).

4.1.52. 2-(4-Aminophenylethynyl)-3-cyanopyridine (**25g**)

Compound **21g** was treated with **24**, CuI, Na ascorbate and (Ph₃P)₂PdCl₂ in Pr₂NH and THF, as for the synthesis of **25b**, to give **25g** (364 mg, 87%), as a dark green powder: mp 128-130°C; ¹H NMR (CDCl₃) δ 3.96 (2 H, br, NH₂), 6.64 (2 H, d, J = 9.1 Hz, Ph 3,5-H₂), 7.30 (1 H, dd, J = 8.5, 1.8 Hz, 5-H), 7.49 (2 H, d, J = 6.6 Hz, Ph 2,6-H₂), 7.92 (1 H, dd, J = 7.9, 1.7 Hz, 4-H), 8.73 (1 H, dd, J = 4.9, 1.7 Hz, 6-H); ¹³C NMR (CDCl₃) δ 82.87 (ethyne 2-C), 98.10 (ethyne 1-C), 106.48 (Ph 1-C), 113.68 (Ph 3,5-C₂), 116.51 (5-C), 121.94 (C≡N), 133.58 (Ph 2,6-C₂), 140.65 (3-C), 145.43 (4-C), 150.12 (6-C), 151.16 (Ph 4-C), 153.27 (2-C); MS m/z 242.0693 (M + Na)⁺ (C₁₄H₉N₃Na requires 242.0694), 220.0876 (M + H)⁺ (C₁₄H₁₀N₃ requires 220.0875).

4.1.53. 3-Cyano-2-((4-phenylmethoxyphenyl)ethynyl)pyridine (25h)

Compound **21h** was treated with **24**, CuI, Na ascorbate and $(\text{Ph}_3\text{P})_2\text{PdCl}_2$ in Pr_2NH and THF, as for the synthesis of **25a**, to give **25h** (29%) as an off-white powder: mp 129–132°C; IR ν_{max} 2215, 2189, 1599, 1506, 1464 cm^{-1} ; ^1H NMR (CDCl_3) δ 5.08 (2 H, s, CH_2), 6.98 (2 H, d, $J = 9.5$ Hz, Ph 3,5- H_2), 7.29 (1 H, dd, $J = 7.9$, 4.9 Hz, 5-H), 7.31–7.44 (5 H, m, Ph'- H_5), 7.62 (2 H, d, $J = 9.5$ Hz, Ph 2,6- H_2), 7.93 (1 H, dd, $J = 1.7$ Hz, 7.9 Hz, 4-H), 8.74 (1 H, dd, $J = 4.9$, 1.7 Hz, 6-H); ^{13}C NMR (CDCl_3) δ 70.06 (CH_2), 85.08 ($\text{C}\equiv\text{N}$), 96.85 (ethyne 2-C), 112.41 (ethyne 1-C), 113.22 (3-C), 115.11 (Ph 2,6- C_2), 116.08 (Ph 1-C), 121.47 (5-C), 127.40 (Ph' 3,5- C_2), 128.11 (Ph' 4-C), 128.60 (Ph' 2,6- C_2), 134.24 (Ph 3,5- C_2), 136.26 (Ph' 1-C), 139.73 (4-C), 146.33 (2-C), 152.73 (6-C), 160.21 (Ph 4-C); MS m/z 333 ($\text{M} + \text{Na}$)⁺, 311.1181 ($\text{M} + \text{H}$)⁺ ($\text{C}_{21}\text{H}_{15}\text{N}_2\text{O}$ requires 311.1179).

4.1.54. 3-Cyano-2-(pyridin-4-ylethynyl)pyridine (25l)

CuI (19.2 mg, 0.10 mmol), $(\text{Ph}_3\text{P})_4\text{Pd}$ (57.8 mg, 0.05 mmol), **24** (184 mg, 1.0 mmol), **21l** (103 mg, 1.0 mmol) and Na ascorbate (19.8 mg, 0.10 mmol) were placed in a flask, which was degassed and filled with Ar. Pr_2NH (10 mL) and DMF (10 mL) were added. The mixture was stirred at 40°C for 10 h. Evaporation and chromatography (petroleum ether / EtOAc 3:1 → 1:1 → 1:3) gave **25l** (58 mg, 28%) as an ivory-coloured powder: mp 110–113°C; ^1H NMR (CDCl_3) δ 7.42 (1 H, dd, $J = 7.6$, 4.9 Hz, 5-H), 7.52 (2 H, d, $J = 4.4$ Hz, Py' 3,5- H_2), 8.01 (1 H, dd, $J = 7.6$, 1.8 Hz, 4-H), 8.65 (2 H, d, $J = 4.7$ Hz, Py' 2,6- H_2), 8.82 (1 H, dd, $J = 4.9$, 1.8 Hz, 6-H); ^{13}C NMR (CDCl_3) δ 88.71 (ethyne 2-C), 92.19 (ethyne 1-C), 113.46 (5-C), 115.54 ($\text{C}\equiv\text{N}$), 123.01 (3-C), 125.84 (Py' 3,5- C_2), 129.03 (Py' 4-C), 139.85 (4-C), 149.97 (Py' 2,6- C_2), 150.55 (6-C), 153.91 (2-C); MS m/z 206.0699 ($\text{M} + \text{H}$)⁺ ($\text{C}_{13}\text{H}_8\text{N}_3$ requires 206.0719).

4.1.55. 7-(4-Methylphenyl)pyrano[4,3-*b*]pyridin-5-one (26b)

Compound **38** (101.5 mg, 0.5 mmol) was boiled under reflux with **37b** (252 mg, 1.0 mmol) and Cs_2CO_3 (163 mg, 0.5 mmol) in MeCN (15 mL) for 10 h. The mixture was cooled and poured into water (10 mL) and the mixture was extracted with CH_2Cl_2 (3 ×). The combined extracts were dried. The evaporation residue was suspended in petroleum ether (50 mL). The mixture was sonicated and was filtered. The collected solid was washed (water, petroleum ether) to give **26b** (110 mg, 93%) as an off-white powder: mp 135–136°C; ^1H NMR (CDCl_3) δ 2.41 (3 H, s, Me), 7.16 (1 H, s, 8-H), 7.28 (2 H, d, $J = 8.0$ Hz, Ph 3,5- H_2), 7.38 (1 H, dd, $J = 7.9$, 4.7 Hz, 3-H), 7.80 (2 H, d, $J = 8.3$ Hz, Ph 2,6- H_2), 8.52 (1 H, ddd, $J = 7.9$, 1.7, 0.6 Hz 4-H), 8.92 (1 H, dd, $J = 4.7$, 1.8 Hz, 2-H); ^{13}C NMR (CDCl_3) δ 21.0 (Me), 102.92 (8-C), 117.0 (4a-C), 123.0 (3-C), 125.55 (Ph 2,6- C_2), 126.0 (Ph 1-C), 129.68 (Ph 3,5- C_2), 137.52 (4-C), 141.0 (4-C), 150.0 (7-C), 156.33 (5-C), 158.0 (2-C), 162.0 (8a-C); MS m/z 238.0850 ($\text{M} + \text{Na}$)⁺ ($\text{C}_{15}\text{H}_{12}\text{NNaO}_2$ requires 238.0863).

4.1.56. 7-(4-Methoxyphenyl)pyrano[4,3-*b*]pyridin-5-one (26c)

Compound **38** (101.5 mg), was treated with **37c**⁴² and Cs_2CO_3 , as for the synthesis of **26b**, to give **26c** (mg, 22%) as an off-white powder: mp 169–171°C (lit.⁵⁴ 177–178°C); ^1H NMR (CDCl_3) δ 3.78 (3 H, s, Me), 6.63 (1 H, s, 8-H), 6.88 (2 H, d, $J = 9.0$ Hz, Ph 3,5- H_2), 7.28 (1 H, dd, $J = 7.5$, 4.0 Hz, 3-H), 7.76 (2 H, d, $J = 8.5$ Hz, Ph 2,6- H_2), 8.41 (1 H, d, $J = 8.0$ Hz, 4-H), 8.81 (1 H, m, 2-H); ^{13}C NMR (CDCl_3) δ 50.43 (Me), 91.46 (Ph 1-C), 101.86 (8-C), 113.77 (4a-C), 116.51 (Ph 3,5- C_2), 122.43 (3-C), 129.49 (Ph 2,6- C_2), 137.67 (4-C), 156.13 (2-C), 157.46 (7-C), 161.77 (8a-C), 163.66 (5-C); MS (ESI in MeOH, which converts **13c** to methyl 2-(2-(4-methoxyphenyl)-2-oxoethyl)pyridine-3-carboxylate) m/z 286.1075 ($\text{M} + \text{H}$)⁺ ($\text{C}_{16}\text{H}_{16}\text{NO}_4$ requires 286.1082).

4.1.57. 7-(4-Chlorophenyl)pyrano[4,3-*b*]pyridin-5-one (26e)

Compound **38** (101.5 mg, 0.5 mmol) was boiled under reflux with **37e** (146.5 mg, 0.5 mmol) and Cs_2CO_3 (163 mg, 0.5 mmol) in MeCN (15 mL) for 12 h. The mixture was cooled and poured into water. The mixture was extracted (EtOAc, 3 ×). The combined extracts were washed (brine) and dried. The evaporation residue was washed (petroleum ether) to give **26e** (80 mg, 63%) as an off-white powder: mp 188–190°C; ^1H NMR (CDCl_3) δ 7.13 (1 H, s, 8-H), 7.36 (1 H, dd, $J = 8.0$, 5.0 Hz, 3-H), 7.40 (2 H, d, $J = 8.5$ Hz, Ph 3,5- H_2), 7.78 (2 H, d, $J = 8.5$ Hz, Ph 2,6- H_2), 8.47 (1 H, d, $J = 8.0$ Hz, 4-H), 8.87 (1 H, d, $J = 4.5$ Hz, 2-H); ^{13}C NMR (CDCl_3) δ 117.02 (8a-C), 123.02 (3-C), 126.91 (Ph 3,5- C_2), 129.34 (Ph 2,6- C_2), 129.83 (8-C), 136.98 (Ph 4-C), 137.62 (4-C), 154.87 (7-C), 156.19 (4a-C), 156.49 (2-C), 161.78 (5-C); MS (ESI in MeOH, which converts **26e** into methyl 2-(2-(4-chlorophenyl)-2-oxoethyl)pyridine-3-carboxylate) m/z 292.0582 ($\text{M} + \text{H}$)⁺ ($\text{C}_{15}\text{H}_{13}^{37}\text{ClNO}_3$ requires 292.0554), 290.0590 ($\text{M} + \text{H}$)⁺ ($\text{C}_{15}\text{H}_{13}^{35}\text{ClNO}_3$ requires 290.0578).

4.1.58. 7-(4-Bromophenyl)pyrano[4,3-*b*]pyridin-5-one (26f)

Compound **38** was treated with **37f** Cs_2CO_3 , as for the synthesis of **26e**, to give **26f** (93%) as an off-white powder: mp 170–171°C; ^1H NMR (CDCl_3) δ 7.25 (1 H, s, 8-H), 7.47 (1 H, dd, $J = 8.0$, 5.0 Hz, 3-H), 7.66 (2 H, d, $J = 8.5$ Hz, Ph 3,5- H_2), 7.81 (2 H, d, $J = 8.5$ Hz, Ph 2,6- H_2), 8.57 (1 H, d, $J = 8.0$ Hz, 4-H), 8.97 (1 H, d, $J = 4.5$ Hz, 2-H); ^{13}C NMR (CDCl_3) δ 104.01 (8-C), 117.01 (4a-C), 123.12 (3-C), 125.36 (Ph 4-C), 127.09 (Ph 2,6- C_2), 130.28 (Ph 1-C), 132.30 (Ph 3,5- C_2), 137.65 (4-C), 154.85 (8a-C), 156.27 (3-C), 156.49 (2-C), 161.78 (5-C); MS (ESI in MeOH, which converts **26f** into methyl 2-(2-(4-bromophenyl)-2-oxoethyl)pyridine-3-carboxylate) m/z 336.0074 ($\text{M} + \text{H}$)⁺ ($\text{C}_{15}\text{H}_{13}^{81}\text{BrNO}_3$ requires 336.0054), 334.0063 ($\text{M} + \text{H}$)⁺ ($\text{C}_{15}\text{H}_{13}^{79}\text{BrNO}_3$ requires 334.0073).

4.1.59. 3-Cyano-4-(phenylethynyl)pyridine (28a)

4-Bromo-3-cyanopyridine **27** (92 mg, 0.5 mmol) in THF (5 mL) was added to CuI (9.6 mg, 50 μmol), $(\text{Ph}_3\text{P})_4\text{Pd}$ (29 mg, 25 μmol) and Na ascorbate (9.9 mg, 50 μmol) in Et_3N (5 mL) under Ar. The mixture was stirred at 40°C for 30 min. Phenylethyne **21a** (76.5 mg, 0.75 mmol) was added and the mixture was stirred at 40°C for 10 h. Evaporation and chromatography (petroleum ether / EtOAc 3:1) gave **28a** (80 mg, 78%) as an off-white powder: mp 74–75°C (lit.⁵³ 85–87°C); IR ν_{max} 2222, 2150, 1582, 1495 ($\text{C}\equiv\text{N}$) cm^{-1} ; ^1H NMR (CDCl_3) δ 7.39–7.43 (3 H, m, Ph 3,4,5- H_3), 7.45 (1 H, d, $J = 5.2$ Hz, 5-H), 7.63 (2 H, d, $J = 8.2$ Hz, Ph 2,6- H_2), 8.75 (1 H, d, $J = 5.2$ Hz, 6-H), 8.87 (1 H, s, 2-H); ^{13}C NMR (CDCl_3) δ 83.50 (ethyne 2-C), 101.29 (ethyne 1-C), 111.74 (4-C), 115.54 ($\text{C}\equiv\text{N}$), 120.76 (Ph 1-C), 125.06 (5-C), 128.59 (Ph 3,5- C_2), 130.28 (Ph 4-C), 132.38 (Ph 2,6- C_2), 134.87 (3-C), 152.40 (2-C), 152.68 (6-C); MS m/z 227.0569 ($\text{M} + \text{Na}$)⁺ ($\text{C}_{14}\text{H}_8\text{N}_2\text{Na}$ requires 227.0585).

4.1.60. 3-Cyano-4-(4-methoxyphenylethynyl)pyridine (28c)

Compound **27** was treated with CuI, $(\text{Ph}_3\text{P})_4\text{Pd}$, Na ascorbate and **21c** in Et_3N and THF, as for the synthesis of **28a**, except that the chromatographic eluent was petroleum ether / EtOAc (3:1 → 2:1), to give **28c** (68%) as a yellow powder: mp 101–102°C; IR ν_{max} 2218, 2184, 1608, 1581, 1515 cm^{-1} ; ^1H NMR (CDCl_3) δ 3.84 (3 H, s, Me), 6.90 (2 H, d, $J = 9.0$ Hz, Ph 3,5- H_2), 7.43 (1 H, d, $J = 5.3$ Hz, 5-H), 7.57 (2 H, d, $J = 9.0$ Hz, Ph 2,6- H_2), 8.71 (1 H, d, $J = 8.0$, 6-H), 8.84 (1 H, s, 2-H); ^{13}C NMR (CDCl_3) δ 55.34 (CH_3), 82.96 (ethyne 1-C), 102.12 (ethyne 2-C), 112.80 (3-C), 114.07 ($\text{C}\equiv\text{N}$), 114.30 (Ph 3,5- C_2), 115.66 (Ph 1-C), 124.72 (5-C), 134.18 (Ph 2,6- C_2), 135.31 (4-C), 152.23 (6-C), 152.63 (2-C), 161.25 (Ph 4-C); MS m/z 257.0695 ($\text{M} + \text{Na}$)⁺ ($\text{C}_{15}\text{H}_{10}\text{N}_2\text{NaO}$ requires 257.0691).

4.1.61. 3-Cyano-4-(4-trifluoromethylphenylethynyl)pyridine (28d)

Compound **27** was treated with CuI, (Ph₃P)₄Pd, Na ascorbate and **21d** in Et₃N and THF, as for the synthesis of **28c**, to give **28d** (44%) as a yellow powder: mp 66–68°C; IR $\nu_{\max}$ 2232, 1612, 1568, 1173 cm⁻¹; ¹H NMR (CDCl₃) δ 7.49 (1 H, d, J = 5.2 Hz, 5-H), 7.74 (2 H, d, J = 8.2 Hz, Ph 3,5-H₂), 8.58 (1 H, d, J = 5.4 Hz, 6-H), 8.80 (2 H, d, J = 8.0 Hz, Ph 3,5-H₂), 8.91 (1 H, s, 2-H); ¹³C NMR (CDCl₃) δ 85.10 (ethyne 2-C), 101.20 (ethyne 1-C), 116.20 (3-C), 125.15 (5-C), 125.57 (Ph 2,6-C₂), 132.63 (Ph 3,5-C₂), 133.00 (4-C), 152.59 (6-C); ¹⁹F NMR (CDCl₃) δ -63.07 (CF₃); MS m/z 273.0636 (M + H)⁺ (C₁₅H₈F₃N₂ requires 273.0634).

4.1.62. 4-(4-Chlorophenylethynyl)-3-cyanopyridine (28e)

Compound **27** was treated with CuI, (Ph₃P)₄Pd, Na ascorbate and **21e** in Et₃N and THF, as for the synthesis of **28c**, to give **28e** (59%) as a yellow powder: mp 79–81°C; IR $\nu_{\max}$ 2232, 1569, 724 cm⁻¹; ¹H NMR (CDCl₃) δ 7.37 (2 H, d, J = 8.4 Hz, Ph 2,6-H₂), 7.47 (1 H, d, J = 5.2 Hz, 5-H), 7.55 (2 H, d, J = 8.4 Hz, Ph 3,5-H₂), 8.75 (1 H, d, J = 5.2 Hz, 6-H), 8.87 (1 H, s, 2-H); ¹³C NMR (CDCl₃) δ 99.55 (1-ethyne), 111.70 (3-C), 114.97 (C $\equiv$ N), 119.28 (Ph 1-C), 124.96 (2-C), 129.05 (Ph 2,6-C₂), 133.57 (Ph 3,5-C₂), 137.80 (Ph 4-C), 152.45 (5-C), 152.70 (6-C); MS m/z 263.0156 (M + Na)⁺ (C₁₄H₇³⁷ClN₂Na requires 263.0166), 261.0183 (M + Na)⁺ (C₁₄H₇³⁵ClN₂Na requires 261.0196).

4.1.63. 4-(4-Aminophenylethynyl)-4-cyanopyridine (28g)

Compound **27** was treated with CuI, (Ph₃P)₄Pd, Na ascorbate and **21g** in Et₃N and THF, as for the synthesis of **28c**, to give **28g** (35%) as an orange powder: mp 155–159°C; IR $\nu_{\max}$ 3447, 2218, 2184, 1631, 1603, 1579 cm⁻¹; ¹H NMR (CDCl₃) δ 4.01 (2 H, br, NH₂), 6.63 (2 H, d, J = 8.7 Hz, Ph 3,5-H₂), 7.40 (1 H, d, J = 4.5 Hz, 5-H), 7.44 (2 H, d, J = 8.7 Hz, Ph 2,6-H₂), 8.67 (1 H, d, J = 5.1 Hz, 6-H), 8.81 (1 H, s, 2-H); ¹³C NMR (CDCl₃) δ 82.71 (ethyne 1-C), 103.5 (ethyne 2-C), 109.71 (Ph 1-C), 111.22 (3-C), 114.56 (Ph 3,5-C₂), 124.49 (5-C), 134.23 (Ph 2,6-C₂), 136.10 (4-C), 148.55 (Ph 4-C), 152.09 (Ph 4-C), 152.61 (2-C); MS m/z 242.0681 (M + Na)⁺ (C₁₄H₉N₃Na requires 242.0694).

4.1.64. 2-Methyl-8-oxo-6-phenyl-2,7-naphthyridin-2-ium iodide (29a)

MeI (228 mg, 1.5 mmol) was stirred with **11a** (55 mg, 0.24 mmol) in dry DMF (5 mL) for 72 h. The mixture was poured into EtOAc (2 mL), followed by petroleum ether (20 mL). The solid was collected, washed (petroleum ether) and dried to give **29a** (10 mg, 11%) as a yellow solid: mp 280–283°C (decomp.); ¹H NMR δ 4.41 (3 H, s, Me), 7.28 (1 H, s, 4-H), 7.64–7.69 (3 H, m, Ph 3,4,5-H₃), 7.95 (2 H, d, J = 8.2 Hz, Ph 2,6-H₂), 8.20 (1 H, d, J = 6.7 Hz, 5-H), 8.82 (1 H, d, J = 6.4 Hz, 6-H), 9.71 (1 H, s, 8-H), 12.75 (1 H, br, NH); ¹³C NMR δ 35.77 (Me), 101.16 (4-C), 120.70 (8a-C), 123.33 (5-C), 127.75 (Ph 2,6-C₂), 129.12 (Ph 3,5-C₂), 131.61 (Ph 4-C), 132.12 (Ph 1-C), 143.76 (3-C), 147.25 (6-C), 147.47 (8-C), 152.06 (1-C), 160.83 (4a-C); MS m/z 237.1038 (M + H)⁺ (C₁₅H₁₃N₂O requires 237.1022).

4.1.65. 4-Cyano-3-(phenylethynyl)pyridine (35a)

Compound **34** (91.5 mg, 0.5 mmol) was stirred with (PPh₃)₄Pd (30 mg, 25 μ mol), CuI (9.6 mg, 50 μ mol) and Na ascorbate (9.9 mg, 50 μ mol) in THF (5 mL) and Pr₂NH (5 mL) at 40°C under Ar for 30 min. PhC $\equiv$ CH **21a** (102 mg, 1.0 mmol) was added and the mixture was stirred at 40°C under Ar for 16 h. Cooling, evaporation and chromatography (petroleum ether / EtOAc 4:1 $\rightarrow$ 1:3) gave **35a** (55 mg, 50%) as a pale buff powder: mp 46–48°C (lit.⁵³ 49–53°C); IR $\nu_{\max}$ 2222, 2150, 1582 cm⁻¹; ¹H NMR (CDCl₃) δ 7.40 (3 H, m, Ph 3,4,5-H₃), 7.53 (1 H, d, J = 4.9 Hz, 5-H), 7.62 (2 H, d, J = 9.6 Hz, Ph 2,6-H₂), 8.68 (1 H, d, J = 4.9 Hz, 6-H), 8.92 (1 H, s, 2-H); ¹³C NMR (CDCl₃) δ 82.54 (1-C), 99.49 (2-C), 115.57 (C $\equiv$ N), 121.28 (Ph 1-C), 122.35 (3-C), 124.95 (5-C),

128.36 (4-C), 128.52 (Ph 3,5-C₂), 129.78 (Ph 4-C), 132.09 (Ph 2,6-C₂), 148.40 (6-C), 152.77 (2-C); MS m/z 227.0590 (M + Na)⁺ (C₁₄H₈N₂Na requires 227.0580).

4.1.66. 4-Cyano-3-(4-methylphenylethynyl)pyridine (35b)

1-Ethynyl-4-methylbenzene **21b** was treated with **34**, CuI, (PPh₃)₄Pd and Na ascorbate in THF and Pr₂NH, as for the synthesis of **35a**, except that the chromatographic eluent was petroleum ether / EtOAc (4:1 $\rightarrow$ 3:2) to give **35b** (62%) as a pale buff powder: mp 94–96°C; ¹H NMR (CDCl₃) δ 2.39 (3 H, s, Me), 7.20 (2 H, d, J = 8.4 Hz, Ph 3,5-H₂), 7.51 (3 H, m, 5-H, Ph 2,6-H₂), 8.65 (1 H, d, J = 5.0 Hz, 6-H), 8.90 (1 H, s, 2-H); ¹³C NMR (CDCl₃) δ 21.62 (Me), 100.01 (ethynyl 1-C), 113.20 (C $\equiv$ N), 114.90 (ethynyl 2-C), 119.50 (Ph 1-C), 123.50 (4-C), 124.90 (5-C), 129.15 (Ph 4-C), 129.31 (Ph 3,5-C₂), 132.03 (Ph 2,6-C₂), 140.50 (3-C), 148.15 (6-C), 152.02 (2-C); MS m/z 219.0910 (M + H)⁺ (C₁₅H₁₁N₂ requires 219.0922).

4.1.67. 4-Cyano-3-(4-methoxyphenylethynyl)pyridine (35c)

Compound **21c** was treated with **34**, (PPh₃)₄Pd, CuI and Na ascorbate in THF and Pr₂NH, as for the synthesis of **35b**, to give **35c** (72%) as a pale buff powder: mp 96–97°C; ¹H NMR (CDCl₃) δ 3.85 (3 H, s, Me), 6.91 (2 H, d, J = 8.9 Hz, Ph 3,5-H₂), 7.55 (1 H, d, J = 5.0 Hz, 5-H), 7.56 (2 H, d, J = 8.9 Hz, Ph 2,6-H₂), 8.64 (1 H, d, J = 5.0 Hz, 6-H), 8.88 (1 H, s, 2-H); ¹³C NMR (CDCl₃) δ 55.35 (Me), 81.72 (ethynyl 1-C), 99.99 (ethynyl 2-C), 113.28 (Ph 1-C), 114.22 (Ph 3,5-C₂), 115.44 (C $\equiv$ N), 121.92 (4-C), 122.93 (3-C), 124.87 (5-C), 133.77 (Ph 2,6-C₂), 147.92 (6-C), 152.57 (2-C), 160.81 (Ph 4-C); MS m/z 235.0854 (M + H)⁺ (C₁₅H₁₀N₂O requires 235.0827).

4.1.68. 4-Cyano-3-(4-trifluoromethylphenylethynyl)pyridine (35d)

Compound **21d** was treated with **34**, (PPh₃)₄Pd, CuI and Na ascorbate in THF and Pr₂NH, as for the synthesis of **35b**, to give **35d** (48%) as a pale orange powder: mp 39–40°C; ¹H NMR (CDCl₃) δ 7.57 (1 H, d, J = 5.0 Hz, 5-H), 7.67 (2 H, d, J = 8.0 Hz, Ph 3,5-H₂), 7.74 (2 H, d, J = 8.0 Hz, Ph 2,6-H₂), 8.73 (1 H, d, J = 5.0 Hz, 6-H), 8.95 (1 H, s, 2-H); ¹³C NMR (CDCl₃) δ 84.49 (ethynyl 2-C), 97.52 (ethynyl 1-C), 115.15 (C $\equiv$ N), 121.76 (3-C), 122.21 (4-C), 123.29 (q, J = 298.3 Hz, CF₃), 125.05 (5-C), 125.55 (q, J = 3.6 Hz, Ph 3,5-C₂), 131.45 (q, J = 32.8 Hz, Ph 4-C), 132.39 (Ph 2,6-C₂), 149.13 (6-C), 152.89 (2-C); ¹⁹F NMR (CDCl₃) δ -63.00 (s, CF₃); MS m/z 295.0451 (M + Na)⁺ (C₁₅H₇F₃N₂Na requires 295.0454).

4.1.69. 3-(4-Chlorophenylethynyl)-4-cyanopyridine (35e)

Compound **21e** was treated with **34**, (PPh₃)₄Pd, CuI and Na ascorbate in THF and Pr₂NH, as for the synthesis of **35b**, to give **35e** (41%) as a pale buff powder: mp 200–201°C; ¹H NMR (CDCl₃) δ 7.38 (2 H, d, J = 6.7 Hz, Ph 2,6-H₂), 7.53 (1 H, m, 5-H), 7.56 (2 H, d, J = 6.7 Hz, Ph 3,5-H₂), 8.69 (1 H, d, J = 5.5 Hz, 6-H), 8.91 (1 H, s, 2-H); ¹³C NMR (CDCl₃) δ 92.02 (ethynyl 2-C), 98.70 (ethynyl 1-C), 113.94 (C $\equiv$ N), 118.96 (Ph 4-C), 119.21 (3-C), 123.90 (4-C), 124.55 (5-C), 133.28 (Ph 3,5-C₂), 133.64 (Ph 2,6-C₂), 135.71 (Ph 1-C), 148.66 (6-C), 152.72 (2-C); MS m/z 239.0391 (M + H)⁺ (C₁₄H₈³⁵ClN₂ requires 239.0371).

4.1.70. 7-(4-Methoxyphenyl)-2-methyl-5-oxo-2,6-naphthyridin-2-ium iodide (36c)

MeI (228 mg, 1.6 mmol) was stirred with **10c** (35 mg, 0.13 mmol) in dry DMF (5 mL) for 36 h. The mixture was poured into EtOAc (3 mL). The solid was collected, washed (Me₂CO) and dried to give **36c** (26 mg, 52%) as a yellow solid: mp 263–265°C; ¹H NMR δ 3.91 (3 H, s, OMe), 4.51 (3 H, br, NMe), 7.15 (1 H, s, 8-H), 7.18 (2 H, d, J = 8.9 Hz, Ph 3,5-H₂), 7.85 (2 H, d, J = 8.9 Hz, Ph 2,6-H₂), 8.63 (1 H, d, J = 6.1 Hz, 4-H), 8.80 (1 H, d, J = 6.4 Hz, 3-H), 9.59 (1 H, br, NH); ¹³C NMR δ 48.65 (NMe), 55.51

(OMe), 98.47 (8-C), 114.51 (Ph 3,5-C₂), 124.64 (4-C), 124.71 (Ph 1-C), 128.85 (Ph 2,6-C₂), 131.93 (8a-C), 138.94 (3-C), 146.18 (7-C), 147.21 (1-C), 160.08 (4a-C), 161.24 (Ph 4-C), 162.31 (5-C); MS *m/z* 267.1127 (M)⁺ (C₁₆H₁₅N₂O₂ requires 267.1128).

4.1.71. 3-(4-Methylphenyl)pyrano[3,4-*c*]pyridin-1-one (40b)

Compound **39** (101.5 mg, 0.5 mmol) was heated under reflux with **37b** (252 mg, 1.0 mmol) and Cs₂CO₃ (163 mg, 0.5 mmol) in MeCN (15 mL) for 2 d. The mixture was cooled, poured into water and extracted thrice with CH₂Cl₂. The combined extracts were dried. The evaporation residue was suspended in petroleum ether (50 mL) and sonicated. The solid was collected and washed (water, petroleum ether) to give **40b** (38 mg, 32%) as an off-white powder: mp 120-123°C; ¹H NMR (CDCl₃) δ 2.45 (3 H, s, Me), 6.90 (1 H, s, 4-H), 7.31 (2 H, d, *J* = 8.0 Hz, Ph 3,5-H₂), 7.33 (1 H, d, *J* = 5.5 Hz, 5-H), 7.83 (2 H, d, *J* = 8.0 Hz, Ph 2,6-H₂), 8.83 (1 H, d, *J* = 5.5 Hz, 6-H), 9.49 (1 H, s, 8-H); ¹³C NMR (CDCl₃) δ 20.5 (Me), 100.0 (4-C), 118.0 (4a-C), 118.5 (5-C), 121.5 (Ph 1-C), 125.80 (Ph 2,6-C₂), 128.9 (Ph 4-C), 129.79 (Ph 3,5-C₂), 130.0 (3-C), 139.5 (8-C), 141.0 (8a-C), 154.0 (6-C), 159.5 (1-C); MS *m/z* 238.0851 (M + H)⁺ (C₁₅H₁₂NO₂ requires 238.0863).

4.1.72. 3-(4-Methoxyphenyl)pyrano[3,4-*c*]pyridin-1-one (40c)

Compound **39** (101.5 mg, 0.5 mmol) was heated under reflux with **37c** (142 mg, 0.5 mmol) and Cs₂CO₃ (163 mg, 0.5 mmol) in MeCN (15 mL) for 2 d. The cooled mixture was poured into water and extracted CH₂Cl₂ (3 ×). The combined extracts were washed (brine) and dried. The evaporation residue was washed (petroleum ether) to give **40c** (16.3 mg, 13%) as an off-white powder: mp 185-186°C; ¹H NMR (CDCl₃) δ 3.91 (3 H, s, Me), 6.76 (1 H, s, 4-H), 6.96 (2 H, d, *J* = 8.5 Hz, Ph 3,5-H₂), 7.33 (1 H, d, *J* = 5.5 Hz, 5-H), 7.88 (2 H, d, *J* = 8.5 Hz, Ph 2,6-H₂), 8.81 (1 H, d, *J* = 5.5 Hz, 6-H), 9.47 (1 H, s, 8-H); ¹³C NMR (CDCl₃) δ 55.49 (Me), 91.51 (4-C), 109.0 (Ph 1-C), 114.48 (Ph 3,5-C₂), 119.0 (5-C), 127.56 (Ph 4-C), 128.23 (Ph 2,6-C₂), 131.38 (3-C), 141.0 (8a-C), 143.0 (6-C), 152.8 (8-C), 163.03 (1-C); MS (ESI in MeOH, which converts **40c** to methyl 4-(2-(4-methoxyphenyl)-2-oxoethyl)pyridine-3-carboxylate) *m/z* 286.1074 (M + H)⁺ (C₁₆H₁₆NO₄ requires 286.1082).

4.1.73. 3-(4-Bromophenyl)pyrano[3,4-*c*]pyridin-1-one (40f)

Compound **39** (101.5 mg, 0.5 mmol) was boiled under reflux with **37f** (382 mg, 1.0 mmol) and Cs₂CO₃ (163 mg, 0.5 mmol) in MeCN (15 mL) for 3 d. The cooled mixture was poured into water and extracted EtOAc (3 ×). The combined extracts were washed (brine) and dried. The evaporation residue was washed (petroleum ether) to give **40f** (10 mg, 7%) as a pale buff gum: ¹H NMR (CDCl₃) δ 6.83 (1 H, s, 4-H), 7.36 (2 H, d, *J* = 8.5 Hz, Ph 3,5-H₂), 7.69 (2 H, d, *J* = 8.5 Hz, Ph 2,6-H₂), 7.90 (1 H, dd, *J* = 8.5, 4.5 Hz, 5-H), 8.73 (1 H, d, *J* = 4 Hz, 6-H), 9.37 (1 H, s, 8-H); ¹³C NMR (CDCl₃) δ 92.50 (4-C), 118.50 (3-C), 119.03 (4a-C), 127.35 (Ph 3,5-C₂), 129.86 (Ph 1-C), 132.05 (Ph 2,6-C₂), 134.50 (Ph 4-C), 143.46 (8a-C), 152.24 (8-C), 153.91 (6-C), 165.04 (1-C); MS (ESI in MeOH, which converts **40f** into methyl 4-(2-(4-bromophenyl)-2-oxoethyl)pyridine-3-carboxylate) *m/z* 336.0011 (M + H)⁺ (C₁₅H₁₃⁸¹BrNO₃ requires 336.0054), 334.0066 (M + H)⁺ (C₁₅H₁₃⁷⁹BrNO₃ requires 334.0073).

4.1.74. 3-Phenylpyrano[4,3-*c*]pyridin-1-one (41a)

Compound **31** (101.5 mg, 0.5 mmol) was stirred with **37a** (114 mg, 0.5 mmol), K₃PO₄ (212 mg, 1.0 mmol) and CuI (10 mg, 50 μmol) in dry DMF (7 mL) at 100°C under Ar for 6 d. Water (7 mL) was added to the cooled mixture. The mixture was extracted EtOAc (3 ×). The combined extracts were dried. Evaporation and chromatography (petroleum ether: EtOAc 5:1 → 3:1) gave **41a** (7.6 mg, 7%) as a yellow powder: mp 171-173°C (lit.⁵³ 166-

168°C); ¹H NMR (CDCl₃) δ 7.02 (1 H, s, 4-H), 7.48 (3 H, m, Ph 3,4,5-H₃), 7.89 (2 H, m, Ph 2,6-H₂), 8.06 (1 H, d, *J* = 5.2 Hz, 8-H), 8.76 (1 H, d, *J* = 5.1 Hz, 7-H), 8.97 (1 H, s, 5-H); ¹³C NMR δ 98.52 (4-C), 118.0 (8-C), 125.42 (Ph 2,6-C₂), 127.00 (8a-C), 129.01 (Ph 3,5-C₂), 130.64 (Ph 4-C), 131.00 (Ph 1-C), 132.00 (3-C), 148.44 (7-C), 149.00 (5-C), 151.00 (1-C); MS *m/z* 224.0708 (M + H)⁺ (C₁₄H₁₀NO₂ requires 224.0712).

4.1.75. 6-Benzyl-2-phenyl-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-one (47a)

Compound **46** (1.42 g, 5.0 mmol) was boiled under reflux with **45a** (600 mg, 5.0 mmol) and NaOMe (from Na (690 mg, 30 mmol)) in dry MeOH (30 mL) for 10 h, then cooled. The evaporation residue, in water, was sonicated for 5 min. The suspension was kept at 2-8°C for 1 h. The solid was collected, washed (water, EtOAc) and dried to give **47a** (840 mg, 53%) as an off-white powder: mp 233-235°C; ¹H NMR δ 2.70-2.74 (4 H, m, 7,8-H₄), 3.24 (2 H, s, 5-H₂), 3.69 (2 H, s, PhCH₂N), 7.28-7.37 (5 H, m, Ph(Bn) 2,3,4,5,6-H₅), 7.47-7.53 (3 H, m, Ph 3,4,5-H₃), 8.08 (2 H, d, *J* = 7.0 Hz, Ph 2,6-H₂); 12.50 (1 H, br, NH); ¹³C NMR δ 31.38 (8-C), 49.12 (7-C), 49.45 (5-C), 61.70 (Ph-CH₂-N), 117.0 (4a-C), 127.01 (Ph(Bn) 4-C), 127.46 (Ph 2,6-C₂), 128.24 (Ph 2,6-C₂), 128.43 (Ph(Bn) 3,5-H₂), 128.78 (Ph(Bn) 2,6-H₂), 138.31 (Ph 1-C), 139.0 (Ph(Bn) Ph 1-C), 145.0 (8a-C), 153.5 (4-C), 159.0 (2-C); MS *m/z* 318.1586 (M + H)⁺ (C₂₀H₂₀N₃O requires 318.1601).

4.1.76. 6-Benzyl-2-(4-methylphenyl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-one (47b)

Compound **46** was treated with **45b** and NaOMe, as for the synthesis of **47a**, to give **47b** (56%) as an off-white powder: mp 234-235°C; ¹H NMR δ 2.37 (3 H, s, Me), 2.69-2.73 (4 H, m, 7,8-H₄), 3.24 (2 H, s, 5-H₂), 3.69 (2 H, s, PhCH₂N), 7.29-7.31 (3 H, m, Ph 4-H, Ar 3,5-H₂), 7.34-7.37 (4 H, m, Ph 2,3,5,6-H₄), 7.98 (2 H, d, *J* = 8.0 Hz, Ar 2,6-H₂); 12.50 (1 H, br, NH); ¹³C NMR δ 21.0 (Me), 32.0 (8-C), 49.5 (7-C), 49.8 (5-C), 62.0 (PhCH₂N), 125.8 (4a-C), 126.0 (Ph 4-C), 127.41 (Ar 2,6-C₂), 128.24 (Ar 3,5-C₂), 128.79 (Ph 2,6-C₂), 129.08 (Ph 3,5-C₂), 132.0 (Ar 1-C), 140.0 (Ph 1-C), 142.0 (Ar 4-C), 158.0 (8a-C), 161.5 (4-C), 175.0 (2-C); MS *m/z* 685 (2 M + Na)⁺, 663.3494 (2 M + H)⁺ (C₄₂H₄₃N₆O₂ requires 663.3447), 354.1592 (M + Na)⁺ (C₂₁H₂₁N₃NaO requires 354.1582), 332.1747 (M + H)⁺ (C₂₁H₂₂N₃O requires 332.1757).

4.1.77. 6-Benzyl-2-(4-trifluoromethylphenyl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-one (47d)

Compound **46** was treated with **45d** and NaOMe, as for the synthesis of **47a**, to give **47d** (60%) as an off-white powder: mp 234-235°C; ¹H NMR δ 2.66-2.73 (4 H, m, 7,8-H₄), 3.24 (2 H, s, 5-H₂), 3.70 (2 H, s, PhCH₂N), 7.39-7.41 (5 H, m, Ph 2,3,4,5,6-H₅), 7.77 (2 H, d, *J* = 7.8 Hz, Ar 3,5-H₂), 8.44 (2 H, d, *J* = 7.7 Hz, Ar 2,6-H₂), 12.50 (1 H, br, NH); ¹³C NMR δ 31.47 (8-C), 50.14 (7-C), 50.64 (5-C), 62.19 (PhCH₂N), 115.38 (4a-C), 123.36 (q, *J* = 265.0 Hz, CF₃), 124.63 (q, *J* = 3.6 Hz, Ar 2,6-C₂), 126.86 (Ph 4-C), 127.88 (Ph 3,5-C₂), 128.15 (Ar 2,6-C₂), 128.60 (q, *J* = 32 Hz, Ar 4-C), 128.74 (Ph 2,6-C₂), 138.74 (Ph 1-C), 142.81 (Ar 1-C), 156.72 (8a-C), 157.82 (2-C), 169.10 (4-C); ¹⁹F NMR δ -60.77 (CF₃); MS *m/z* 408 (M + Na)⁺, 386.1493 (M + H)⁺ (C₂₁H₁₉F₃N₃O requires 386.1475).

4.1.78. 6-Benzyl-2-(4-chlorophenyl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-one (47e)

Compound **46** was treated with **45e** and NaOMe, as for the synthesis of **47a**, to give **47e** (58%) as an off-white powder: mp 211-213°C; ¹H NMR δ 2.75-2.78 (4 H, m, 7,8-H₄), 3.29 (2 H, s, 5-H₂), 3.74 (2 H, s, PhCH₂N), 7.34-7.42 (5 H, m, Ph 2,3,4,5,6-H₅), 7.61 (2 H, d, *J* = 8.2 Hz, Ar 3,5-H₂), 8.15 (2 H, d, *J* = 7.9 Hz, Ar 2,6-H₂); 12.65 (1 H, br, NH); ¹³C NMR δ 32.00 (8-C), 49.80

(7-C), 49.90 (5-C), 62.00 (PhCH₂N), 128.50 (Ar 3,5-C₂), 128.79 (m, Ph 2,3,4,5,6-C₅), 129.50 (8a-C), 129.80 (Ar 2,6-C₂), 139.00 (4a-C), 154.00 (1-C); MS *m/z* 350.1066 (M + H)⁺ (C₂₀H₁₇³⁵ClN₃O requires 350.1066).

4.1.79. 6-Benzyl-2-(4-bromophenyl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-one (47f)

Compound **46** was treated with **45f** and NaOMe, as for the synthesis of **47a**, to give **47f** (43%) as an off-white powder: mp 253–255°C; ¹H NMR δ 2.70–2.74 (4 H, m, 7,8-H₄), 3.24 (2 H, s, 5-H₂), 3.69 (2 H, s, PhCH₂N), 7.28–7.37 (5 H, m, Ph 2,3,4,5,6-H₅), 7.71 (2 H, d, *J* = 9.0 Hz, Ar 3,5-H₂), 8.05 (2 H, d, *J* = 8.5 Hz, Ar 2,6-H₂); 12.60 (1 H, br, NH); ¹³C NMR δ 32.0 (8-C), 49.5 (7-C), 49.8 (5-C), 62.0 (PhCH₂N), 118.7 (4a-C), 127.03 (Ph 4-C), 128.24 (Ph 2,3,5,6-C₄), 128.78 (Ar 2,6-C₂), 129.52 (Ar 3,5-C₂), 131.49 (Ar 1-C), 139.0 (Ph 1-C), 156.0 (8a-C), 158.0 (8a-C), 163.0 (4-C), 163.5 (4-C); MS *m/z* 398.0665 (M + H)⁺ (C₂₀H₁₉⁸¹BrN₃O requires 398.0688), 396.0686 (M + H)⁺ (C₂₀H₁₉⁷⁹BrN₃O requires 396.0706).

4.1.80. 6-Benzyl-2-(4-phenylethynylphenyl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4(3*H*)-one (47j)

NaOMe (259 mg, 4.8 mmol) in dry MeOH (5 mL) was added to **46** (216 mg, 0.8 mmol) in dry MeOH (5 mL), followed by **45j** (177.5 mg, 0.8 mmol) in dry MeOH (5 mL). The mixture was stirred at reflux for 16 h. The evaporation residue was recrystallised (water) to give **47j** (57%) as an off-white powder: mp 66–67°C; ¹H NMR δ 2.36–2.66 (2 H, m, 8-H₂), 2.86–3.25 (2 H, m, 7-H₂), 3.46–3.63 (2 H, m, 5-H₂), 3.68 (2 H, s, PhCH₂N), 7.24–7.38 (4 H, m, Ph'-2,3,5,6-H₄), 7.45–7.52 (4 H, m, Ph(Bn)-2,3,5,6-H₄), 7.60–7.69 (2 H, m, Ph'-4H, Ph(Bn) 4-H), 7.80 (2 H, d, *J* = 8.1 Hz, Ph 3,5-H₂), 7.96 (2 H, d, *J* = 8.0 Hz, Ph 2,6-H₂); ¹³C NMR δ 29.73 (8-C), 50.22 (7-C), 51.78 (5-C), 59.94 (Bn-CH₂-N), 87.91 (ethynyl 1-C), 93.27 (ethynyl 2-C), 110.95 (Ph 4-C), 118.44 (Ph' 1-C), 121.39 (Bn Ph 1-C), 126.99 (Ph 1-C), 128.77 (Ph' 2,3,5,6-H₄), 128.86 (Bn Ph 2,3,5,6-H₄), 129.53 (Ph' 4-C), 131.62 (Bn Ph 4-C), 132.13 (Ph 3,5-C₂), 132.60 (Ph 2,6-C₂), 138.33 (8a-C), 165.54 (4-C), 169.11 (2-C); MS *m/z* 418.1983 (M + H)⁺ (C₂₈H₂₄N₃O requires 418.1919).

4.1.81. 6-Benzyl-2-(pyridin-4-yl)-5,6,7,8-tetrahydropyrido[4,3-*d*]pyrimidin-4-one (47l)

Compound **46** was treated with **45l** and NaOMe, as for the synthesis of **47a**, to give **47l** (1.27 g, 86%) as an off-white powder: mp 298–300°C; ¹H NMR δ 2.63 (2 H, m, 8-H₂), 2.71 (2 H, m, 7-H₂), 3.23 (2 H, s, 5-H₂), 3.69 (2 H, s, PhCH₂N), 7.31–7.42 (5 H, m, Ph 2,3,4,5,6-H₅), 8.16 (2 H, d, *J* = 4.5 Hz, Py 3,5-H₂), 8.58 (2 H, d, *J* = 4.5 Hz, Py 2,6-H₂), 12.50 (1 H, br, NH); ¹³C NMR δ 31.20 (8-C), 50.50 (7-C), 53.70 (5-C), 62.50 (PhCH₂N), 117.60 (8a-C), 121.55 (Py 3,5-C₂), 128.13 (Ph 4-C), 128.73 (Ph 2,3,5,6-C₄), 139.5 (Ph 1-C), 148.10 (Py 1-C), 149.80 (Py 2,6-C₂), 157.00 (4a-C), 160.10 (3-C), 182.60 (1-C); MS *m/z* 341.1374 (M + Na)⁺ (C₁₉H₁₈N₄NaO requires 341.1378), 319.1532 (M + H)⁺ (C₁₉H₁₉N₄O requires 319.1559).

4.2. Protein crystallography

Protein crystallography experiments were carried out using human TNKS-2. The catalytic domain was expressed, purified and crystallised as previously reported.²⁹ Inhibitors were soaked for 48 h into the crystals in a well solution (0.2 M LiSO₄, 0.1 M Tris-HCl pH 8.5, 24–26% PEG 3350) supplemented with the compound (100 μM) and NaCl (250 mM). Before collection of data, the crystals were briefly soaked in a well solution supplemented with 20% glycerol and flash frozen in liquid N₂.

Data were collected at the Diamond Light Source on beamline I04-1. Diffraction data were processed and scaled with the XDS

package.⁵⁵ The structures were solved using the Difference Fourier method, with the starting phases derived from the TNKS-2 structure (PDB code 3U9H). REFMAC⁵⁶ was used for refinement and COOT⁵⁷ for manual building of the model. Statistics for collection of data and refinement are shown in the Supplementary Data.

Data for structures of **12b** and **17a** have been deposited at the Protein Data Bank with PDB codes 4W5I and 4UX4, respectively.

Acknowledgements

We thank the Association for International Cancer Research (now Worldwide Cancer Research) for financial support towards the biochemical and biological studies (Grant 10-0104). KK received a part-funded studentship from the University of Bath. Protein crystallography work was funded by Biocenter Oulu and Academy of Finland (Grant No. 251314 for LL and Grant No. 266922 for TH). Protein crystallography experiments were performed at the Diamond Light Source (Didcot, UK) beamline I04-1. We are grateful to Local Contacts at Diamond for providing assistance in using the beamline. The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007–2013) under BioStruct-X (Grant Agreement No. 283570).

Supplementary data

Supplementary data associated with this article can be found in the online version at [#####](#)

References

- Smith, S.; Giriat, I.; Schmitt, A.; de Lange, T. *Science* **1998**, *282*, 1484.
- Liscio, P.; Carotti, A.; Ascitti, S.; Karlberg, T.; Bellocchi, D.; Llacuna, L.; Macchiarulo, A.; Aaronson, S. A.; Schöler, H.; Pellicciari, R.; Camaioni, E. *J. Med. Chem.* **2014**, *57*, 2807.
- Paine, H. A.; Nathubhai, A.; Woon, E. C. Y.; Sunderland, P. T.; Wood, P. J.; Mahon, M. F.; Lloyd, M. D.; Thompson, A. S.; Haikarainen, T.; Narwal, M.; Lehtiö, L.; Threadgill, M. D. *Bioorg. Med. Chem.* submitted.
- Nathubhai, A.; Wood, P. J.; Lloyd, M. D.; Thompson, A. S.; Threadgill, M. D. *ACS Med. Chem. Lett.* **2013**, *4*, 1173.
- Haikarainen, T.; Krauss, S.; Lehtiö, L. *Curr. Pharm. Design* **2014**, in press.
- Haikarainen, T.; Narwal, M.; Joensuu, P.; Lehtiö, L. *ACS Med. Chem. Lett.* **2014**, *5*, 18.
- Hua, Z.; Bregman, H.; Buchanan, J. L.; Chakka, N.; Guzman-Perez, A.; Gunaydin, H.; Huang, X.; Gu, Y.; Berry, V.; Liu, J.; Teffera, Y.; Huang, L.; Egge, B.; Emkey, R.; Mullady, E. L.; Schneider, S.; Andrews, P. S.; Acquaviva, L.; Dovey, J.; Mishra, A.; Newcomb, J.; Saffran, D.; Serafino, R.; Strathdee, C. A.; Turci, S. M.; Stanton, M.; Wilson, C.; DiMauro, E. F. *J. Med. Chem.* **2013**, *56*, 10003.
- Tian, X.-H.; Hou, W.-J.; Fang, Y.; Fan, J.; Tong, H.; Bai, S.-L.; Chen, Q.; Xu, H.; Li, Y. *J. Exp. Clin. Cancer Res.* **2013**, *3*, 100.
- Huang, S.-M. A.; Mishina, Y. M.; Liu, S.; Cheung, A.; Stegmeier, F.; Michaud, G. A.; Charlat, O.; Willellette, E.; Zhang, Y.; Wiessner, S.; Hild, M.; Shi, X.; Wilson, C. J.; Mikanin, C.; Myer, V.; Fazal, A.; Tomlinson, R.; Serluca, F.; Shao, W.; Cheng, H.; Shultz, M.; Rau, C.; Schirle, M.; Schlegl, J.; Ghidelli, S.; Fawell, S.; Lu, C.; Curtis, D.; Kirschner, M. W.; Lengauer, C.; Finan, P. M.; Tallarico, J. A.; Bouwmeester, T.; Porter, J. A.; Bauer, A.; Cong, F. *Nature* **2009**, *461*, 614.
- Shultz, M. D.; Cheung, A. K.; Kirby, C. A.; Firestone, B.; Fan, J.; Chen, C. H.-T.; Chen, Z.; Chin, D. N.; DiPietro, L.; Fazal, A.; Feng, Y.; Fortin, P. D.; Gould, T.; Lagu, B.; Lei, H.; Lenoir, F.; Majumdar, D.; Ochala, E.; Palermo, M. G.; Pham, L.; Pu, M.; Smith, T.; Stams, T.; Tomlinson, R. C.; Touré, B. B.; Visser, M.; Wang, R. M.; Waters, N. J.; Shao, W. *J. Med. Chem.* **2013**, *56*, 6495.
- Cook, B. D.; Dynek, J. N.; Chang, W.; Shostak, G.; Smith, S. *Mol. Cell. Biol.* **2002**, *22*, 332.

12. Seimiya, H.; Muramatsu, Y.; Smith, S.; Tsuruo, T. *Mol. Cell. Biol.* **2004**, *24*, 1944.
13. Chang, P.; Coughlin, M.; Mitchison, T. J. *Nature Cell Biol.* **2005**, *7*, 1133.
14. Kim, W.; Kim, M.; Jho, E.-H. *Biochem. J.* **2013**, *450*, 9.
15. Kaminker, P. G.; Kim, S.-H.; Taylor, R. D.; Zebajarian, Y.; Funk, W. D.; Morin, G. B.; Yaswen, P.; Campisi, J. J. *J. Biol. Chem.* **2001**, *276*, 35891.
16. Sbodio, J. I.; Lodish, H. F.; Chi, N.-W. *Biochem. J.* **2002**, *361*, 451.
17. Gelmini, S.; Poggesi, M.; Distant, V.; Bianchi, S.; Simi, L.; Luconi, M.; Casini Raggi, C.; Cataliotti, L.; Pazzaglia, M.; Orlando, C. *Cancer Lett.* **2004**, *216*, 81.
18. Gelmini, S.; Poggesi, M.; Pinzani, P.; Ciullini Mannurita, S.; Cianci, F.; Valanzano, R.; Orlando, C. *Oncol. Rep.* **2006**, *16*, 1261.
19. Campbell, L. J.; Fidler, C.; Eagleton, H.; Peniket, A.; Kusec, R.; Gall, S.; Littlewood, T. J.; Wainscoat, J. S.; Boultonwood, J. *Leukemia* **2006**, *20*, 671.
20. Tang, B.; Wang, J.; Fang, J.; Jiang, B.; Zhang, M.; Wang, Y.; Yang, Z. *J. Clin. Neurosci.* **2012**, *19*, 139.
21. Gao, J.; Zhang, J.; Long, Y.; Tian, Y.; Lu, X. *Br. J. Cancer* **2006**, *94*, 341.
22. Gelmini, S.; Quattrone, S.; Malentacchi, F.; Villari, D.; Travaglini, F.; Giannarini, G.; Della Melina, A.; Pazzagli, M.; Nicita, G.; Selli, C.; Orlando, C. *Clin. Chem. Lab. Med.* **2007**, *45*, 862.
23. Seimiya, M. *Br. J. Cancer* **2006**, *94*, 341.
24. Waaler, J.; Machon, O.; Tumova, L.; Dinh, H.; Korinek, V.; Wilson, S. R.; Paulsen, J. E.; Pedersen, N. M.; Eide, T. J.; Machonova, O.; Gradl, D.; Voronkov, A.; von Kries, J. P.; Krauss, S. *Cancer Res.* **2012**, *72*, 2822.
25. Karlberg, T.; Markova, N.; Johansson, I.; Hammarström, M.; Schütz, P.; Weigelt, J.; Schüler, H. *J. Med. Chem.* **2010**, *53*, 5352.
26. Haikarainen, T.; Koivunen, J.; Narwal, M.; Venkannagari, H.; Obaji, E.; Joensuu, P.; Pihlajaniemi, T.; Lehtiö, L. *ChemMedChem* **2013**, *8*, 1978.
27. Narwal, M.; Haikarainen, T.; Fallarero, A.; Vuorela, P. M.; Lehtiö, L. *J. Med. Chem.* **2013**, *56*, 3507.
28. Narwal, M.; Koivunen, J.; Haikarainen, T.; Obaji, E.; Legala, O. E.; Venkannagari, H.; Joensuu, P.; Pihlajaniemi, T.; Lehtiö, L. *J. Med. Chem.* **2013**, *56*, 7880.
29. Narwal, M.; Venkannagari, H.; Lehtiö, L. *J. Med. Chem.* **2012**, *55*, 1360.
30. Wibberley, D. G. *J. Chem. Soc.* **1962**, 4528.
31. Ames, D. E.; Dodds, W. D. *J. Chem. Soc., Perkin Trans. 1* **1972**, 705.
32. Nishiwaki, N.; Komatsu, M.; Ohshiro, Y. *Synthesis* **1991**, 41.
33. Woon, E. C. Y.; Dhimi, A.; Mahon, M. F.; Threadgill, M. D. *Tetrahedron* **2006**, *62*, 4829.
34. Li, J.; Chen, L.; Chin, E.; Lui, A. S.; Zecic, H. *Tetrahedron Lett.* **2010**, *51*, 6422.
35. Kröhnke, F.; Ellegat, K. *Liebigs Ann. Chem.* **1956**, *600*, 198.
36. Tan, H.; Wang, J.; Zhang, Y.; Xing, Y.; Sun, Q.; Li, R. *Tetrahedron* **2013**, *69*, 8299.
37. Tjosås, F.; Pettersen, N. M.; Fiksdahl, A. *Tetrahedron* **2007**, *63*, 11893.
38. Elangovan, A.; Wang, Y.-H.; Ho, T.-I. *Org. Lett.* **2003**, *5*, 1841.
39. Showalter, H. D. H. *J. Heterocyclic Chem.* **2006**, *43*, 1311.
40. Lord, A.-M.; Mahon, M. F.; Lloyd, M. D.; Threadgill, M. D. *J. Med. Chem.* **2009**, *52*, 868.
41. Bobbit, J. M.; Doolittle, R. E. *J. Org. Chem.* **1964**, *29*, 2298.
42. Woon, E. C. Y.; Sunderland, P. T.; Paine, H. A.; Lloyd, M. D.; Thompson, A. S.; Threadgill, M. D. *Bioorg. Med. Chem.* **2013**, *21*, 5218.
43. Shinkwin, A. E.; Whish, W. J. D.; Threadgill, M. D. *Bioorg. Med. Chem.* **1999**, *7*, 297.
44. Liu, L.; Hu, J.; Wang, X.-C.; Zhong, M.-J.; Liu, X.-Y.; Yang, S.-D.; Liang, Y.-M. *Tetrahedron* **2012**, *68*, 5391.
45. Liu, X.; Fu, H.; Jiang, Y.; Zhao, Y. *Angew. Chem. Int. Ed.* **2009**, *48*, 348.
46. Anbazhagan, M.; Boykin, D. W.; Stephens, C. E. *Synthesis* **2003**, 2467.
47. Tyrrell, R. M.; Pidoux, M. *Cancer. Res.* **1986**, *46*, 2665.
48. Huang, C.; Fu, Y.; Fu, H.; Jiang, Y.; Zhao, Y. *Chem. Commun.* **2008**, 6333.
49. Osselaer, J. P.; Lapiere, C. L. *Eur. J. Med. Chem.* **1974**, *9*, 305.
50. Gelling, I. R.; Wibberley, D. G. *J. Chem. Soc. C* **1969**, 931.
51. Ismail, A. G.; Wibberley, D. G. *J. Chem. Soc. C* **1967**, 2613.
52. Huber, I.; Fülöp, F.; Lázár, J.; Bernáth, G.; Tóth, G. *J. Chem. Soc., Perkin Trans. 1* **1992**, 157.
53. Sakamoto, T.; An-naka, M.; Kondo, Y.; Araki, T.; Yamanaka, H. *Chem. Pharm. Bull.* **1988**, *36*, 1890.
54. Hellal, M.; Bourguignon, J.-J.; Bihel, F. J.-J. *Tetrahedron Lett.* **2008**, *49*, 62.
55. Kabsch, W. *J. Appl. Crystallogr.* **1993**, *26*, 795.
56. Murshudov, G. N.; Skubák, P.; Lebedev, A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. *Acta Cryst.* **2011**, *D67*, 355.
57. Emsley, P.; Cowtan, K. *Acta Cryst.* **2004**, *D60*, 2126.

[Click here to remove instruction text...](#)